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Many strides have been made towards utilizing gene therapy to treat genetic 
disorders in humans. Low gene expression and formulation stability during storage have 
hindered the use of nonviral carriers thus far. The purpose of this research was to 
develop a cationic PLGA-b-bPEI micelle-based delivery system to co-deliver genes and 
small therapeutic drugs to the cell nucleus that could also be lyophilized for long-term 
storage and reconstituted as needed by simply adding water. Several PLGA-b-bPEI 
copolymers were synthesized and characterized for their potential to form 
reconstitutable micelle-based gene therapeutic delivery systems that showed enhanced 
nuclear delivery over other current cationic nonviral delivery systems.  
The first section of this dissertation addresses the characterization of a 
reconstitutable charged polymeric micelle system to assess its suitability for gene 
therapeutics delivery. A PLGA-b-bPEI block copolymer was synthesized and 
characterized for buffering capacity, particle size, zeta potential, complexation ability, 
cytotoxicity, transfection efficiency and reporter gene expression, and retention of 
physicochemical and biological characteristics upon lyophilization and reconstitution. 
Results showed that micelles and micelle/pDNA complexes retained their 
physicochemical characteristics following lyophilization and reconstitution. Transfection 
levels were enhanced using reconstituted complexes compared to their fresh 
counterparts without significant cellular toxicity even with pDNA doses up to 20µg, and 
transfection increased linearly with increasing pDNA dose.  
The second section of this dissertation investigates the use of dexamethasone-
loaded micelles for enhanced nuclear accumulation of a reporter gene. PLGA-b-bPEI 
polymers synthesized in the first section were used to prepare dexamethasone-loaded 
micelles and complexed with pDNA. Gene expression was significantly enhanced using 
dexamethasone-loaded micelle/pDNA complexes compared to blank micelle/pDNA 
complexes, particularly for complexation weight ratios less than 1. Dex-micelles 
achieved gene expression equivalent to the blank system using a fraction of the polymer 
(weight ratio 0.25 versus 1), indicating that dexamethasone increased nuclear 
accumulation of polyplexes. Gene expression was nearly equivalent to a bPEI control 
carrier, leading to future plans of co-loading the micelle system with other types of 
drugs and examining this system’s suitability for specific applications such as treating 
patients suffering from asthma or other inflammatory diseases where dexamethasone 
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“Permanence, perseverance and persistence in spite of all obstacles, 
discouragement, and impossibilities: It is this, that in all things  
distinguishes the strong soul from the weak.”  
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1.1. Gene Therapy 
 
Gene therapy refers to a potential therapeutic strategy that can be employed to 
treat diseases resulting from missing or mutated genes. This approach involves replacing 
the gene of interest with a normal copy, supplementing gene expression, or altering 
gene expression in an effort to rescue abnormalities caused by the presence of a 
defective gene [1-3]. The concept of gene therapy was first established over 50 years 
ago as a potential way to treat patients suffering from genetic defects by replacing 
defective DNA with exogenous “good” DNA [4]. Beginning in the 1960s, researchers 
began investigating ways to permanently introduce foreign DNA into mammalian cells 
after being inspired by work done in the 1940s where pneumococci had been 
transformed [5-12], and the first publications referring to gene therapy appeared in the 
early 1970s [13-15]. Policy makers began discussing the issues relating to and the 
ramifications of gene therapy in the seventies [4, 16-18], and in 1986 the National 
Institutes of Health adopted guidelines pertaining to human somatic-cell gene therapy 
protocols [19], paving the way for the first human clinical trials. Many important 
discoveries made in the 1980s including recombinant DNA techniques [20-23], the 
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development of retroviral vectors [24-34], and successful correction of a genetic disease 
phenotype in vitro [35-37] established human gene therapy as a conceptual reality. 
While attempts to treat patients with gene therapy occurred as early as 1970 [4, 38], it 
was not until 1988 that the first protocol for a human clinical trial for gene therapy 
received approval [19] and the first clinical study was performed in 1990 [39]. Early gene 
therapy models focused on the treatment of diseases caused by single genes such as 
coagulation disorders due to deficiencies in clotting factors [40-44], ADA deficiency [45-
47], and many others but advancement in gene therapy techniques have made it 
possible to expand gene treatment further. To date, more than 900 clinical trials have 
been approved worldwide [48] and gene therapy has been investigated as a method to 
treat many multifaceted disease models including Parkinson’s Disease [49], 
inflammatory arthritis [50], cardiovascular disease [51], muscle diseases [52], diabetes 
[53], and multiple types of cancer [54-57].  
1.2. Gene Vectors 
The basis of gene therapy involves the delivery of a normal gene or nucleic acid 
molecule into the cell or tissue affected by disease. This is a multidimensional problem 
characterized by several challenges that need to be overcome in order to achieve 
successful gene therapy.  A fundamental component of this process is the delivery 
vehicle or gene vector used to carry and introduce the gene into the system. Initial 
attempts at gene transfer in the early 1960s were highly inefficient, making it evident 
that this was an important milestone that needed to be addressed in order to make 
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further advances.  Towards the end of that decade, advancements were made towards 
understanding how viruses were able to transfer their viral genome, and this combined 
with the discovery of recombinant DNA motivated the focus of the next several years of 
research.  By the early 1980s, several researchers demonstrated the ability to achieve 
100% infection efficiency using retroviruses, and several studies demonstrated in vitro 
success in rescuing disease phenotypes in cells from human patients [35-37]. 
Subsequent studies employed several different cell types including epithelial cells, 
fibroblasts, and hepatocytes, optimizing and demonstrating the efficiency and efficacy 
of viral gene delivery.   
1.2.1. Viral Vectors 
Viral vectors can be derived from RNA or DNA viral vectors and include gamma-
retrovirus (including Moloney murine leukemia virus), adenovirus, adeno-associated 
virus, lentivirus (including human immunodeficiency virus), herpes simplex virus, and 
others [58]. Because viral vectors are derived from viruses which have evolved natural 
mechanisms to deliver their genomes into cells, they display very high efficiency at 
transferring genes into cells (known as transduction) [3].  
Retroviral vectors were the first virus-derived vectors to be used for gene 
delivery because they could integrate into the host genome with very high efficiency 
and produce stable gene transfer in the target cells which could potentially lead to long-
term gene expression [59]. Retroviral vectors were among the first vectors used in 
human gene therapy trials starting in 1990 [60]. Among retroviral-derived vectors, the 
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most common is the Moloney murine leukemia virus (MMLV), a simple retrovirus that 
was one of the first retroviruses discovered and it remains widely used in gene therapy 
applications even today [58]. To date over 600 gene therapy clinical trials have used 
retroviruses as vectors to treat diseases ranging from adenosine-deaminase severe 
combined immunodeficiency (ADA-SCID) [61] to familial hypercholesterolemia [62] and 
even for developing tumor vaccines [63]. Some limitations of retroviral vectors are that 
integration can only occur in cells undergoing cell division [59] and they have a small 
gene cargo capacity (approximately 7.5 kb) [64]. Additionally many safety concerns have 
arisen after using retrovirus vectors; for example random integration into the host 
genome can produce harmful side effects such as activation of prooncogenes or in the 
cause of MMLV, the development of leukemia-like symptoms [59, 64, 65].  
Adenovirus was the next viral vector to be utilized in humans, starting with gene 
therapy trials in cystic fibrosis patients in 1993 [66]. Adenoviruses have a higher packing 
capacity than retroviruses so they can be used to deliver larger genes [59]. They can 
enter a variety of cell types and produce gene expression in both dividing and non-
diving cell types, thus overcoming some of the limitations associated with retroviral 
vectors. Adenoviruses produce very high gene transfer and unlike retroviruses they do 
not integrate into the host genome, making them useful for instances where high gene 
expression is desired for a short period of time. Adenoviruses enter the cell through 
receptor-mediated endocytosis [67] and can be amplified into very high titers in the 
laboratory [59]. Some clinical applications of adenovirus include the treatment of cystic 
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fibrosis [66], mesothelioma [68], and colon cancer [69]. The safety of adenovirus has 
also come under scrutiny because adenovirus can revert to its wildtype form, can leak 
viral proteins, and is highly immunogenic, so repeat applications to the host are 
problematic [64].  
Adeno-associated virus are nonpathogenic, can infect a variety of cell types 
including quiescent cells, and like retrovirus it can integrate into the host genome [70]. 
It requires a helper virus for infection [71] and unlike retrovirus it integrates into a 
specific site on the human chromosome [72]. Adeno-associated viruses have been used 
to treat cystic fibrosis [73, 74], hemophilia [75], and Parkinson’s Disease [76]. Some 
disadvantages of this vector are the difficulty in producing large amounts of vector and 
its very limited gene carrying capacity (<5 kb) [77]. The original strains of adeno-
associated virus have been modified using recombinant techniques to expand upon 
some of the shortcomings associated with the original virus but there are still some 
safety concerns associated with these vectors.   
 Lentivirus is a complex virus system considered to be a subset of retrovirus. 
Lentiviral-vectors can be used to transfect both dividing and nondividing cells, and have 
several advantages over adenoviruses and adeno-associated viruses. Lentiviral vectors 
have larger coding capacity [78], similar transduction efficiency as adenovirus and 
adeno-associated virus at lower titer levels [79], and reduced immunogenicity in vivo 
compared to other viral-derived vectors [80, 81]. Lentiviral vectors produce stable gene 
expression in quiescent cells such as neurons [82] and hematopoetic stem cells [83], and 
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have been used to treat many neurological diseases including Parkinson’s Disease [76] 
and Huntington’s Disease [84], control tumor growth [85], and even prevent HIV 
infection [86]. The most commonly used lentivirus is derived from human 
immunodeficiency virus (HIV).  
One of the most promising viral-derived vectors discovered in the quest for an 
ideal gene therapy vehicle is the herpes simplex virus, derived from herpes simplex virus 
type 1 (HSV-1). It is of great interest because of its size and the complexity of its genome 
[58], allowing the delivery of larger transgenes than nearly any other viral-vector [87]. 
Vectors derived from HSV-1 have several favorable features including the lack of 
integration into the host genome, complexity of the virus genome, the capacity to infect 
the nervous system including an ability to spread from neuron to neuron and establish 
latent infections in neurons, and their ability to be controlled using anti-herpetic agents 
such as acyclovir or ganciclovir [87, 88]. HSV-1 has been used to develop vaccines [89], 
anticancer agents/treatment [90], and for the treatment of chronic pain [91].  
Although viral vectors have comprised the majority of successful gene therapy 
efforts in humans, success has come with a price. As mentioned above, numerous 
concerns have arisen regarding the safety of viral vectors.  Although they are extremely 
efficient, the very features that make viral based gene delivery systems attractive also 
limit their usage because of unwanted side effects (Table 1.1). Both retroviruses and 









Tablel.l. Summary of Viral-based Gene Delivery Vectors 
Viral Vector Advantages Disadvantages 
• la rge host spectru m (mitotic/ post -mitotic cells) 
• immunogenic 
• high titers 
• reversalto wild type 
• high tra nsduction efficiency 
• tra nsient gene expression in divid ing Adenovirus • episomal viral genome 
cells (clearance of the episome) 
• wild type ca uses mild disease 
• leakage of viral proteins 
• non-enveloped 
• toxicity 
• large coding capacity 
• immunogenic 
• requ ires divid ing cells 
• high tra nsduction rates in vitro • risk of insertional mutagenesis 
• large host spectrum among divid ing cells • risk of reversion to the wild type 
Retrovirus • system is well studied and known • potential inactivation by complement 
• genomic integration/long term gene expression fractions in the serum 
• vector proteins are not expressed in the host • low titers 
• relatively large coding capacity • low delivery rates in vivo 
• ex-vivo application necessa ry 
• virus recombination 
• in vivo and ex vivo administration possible 
· Iow coding capacity 
Adena-associated • genomic integration/long term gene expression • limited DNA packaging capacity 
virus (AAV) • large host spectrum (mitotic & post-mitotic cells) • integration is not always site-directed 
• no associated huma n disease 





Tab lel .l . (cont inued) 
Viral Vector Advantages Disadvantages 
• immunogenic 
• episomal • differen t viruses have differen t selectivi ty 
Herpes Simplex • ma y produce la ten t infect ion during whole • EBVis oncogenic 
virus (HSV) life span • la ten t virus act ivation 
• accommoda tes large inserts • low t ransduct ion efficiency 
• high t iters • transien t exr: ression by available vectors 
• developings'lstem 
° high t ransduct ion efficiency in vi t ro • system is poorl y understood 
° in vivo administ ra tion possible • low efficiency in vivo 
° large coding capaci ty • insert ion mutagenesis 
lentivirus ° infects and t ransduces mi tot ic and post - • virus recombina t ion 
mi tot ic cells • poten t ial inact ivat ion 
° long dura t ion of gene expression • ex vivo administ ra t ion necessary for 
° large coding capaci ty kera t inocytes 
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beneficial for long-term gene expression but causes problems when integration occurs 
at nondiscriminate sites, and in the case of MMLV can cause leukemia-like symptoms 
[59, 64, 65]. Furthermore, this nonspecificity can give rise to other potentially harmful 
effects in the event that random integration results in mutagenesis or oncogensis. 
Whereas retroviruses integrate themselves into rapidly dividing cells, adenoviruses can 
only integrate themselves into nondividing cells, and therefore need to be 
readministered since their presence is not propagated by cell division.  However, 
readministration of adenoviral gene vectors elicits an immune response that can be 
deadly [92]. Although viral-based carriers have been used in approximately 70% of the 
human clinical trials to date [48], alternative nonviral based vectors are rapidly gaining 
popularity in an effort to produce a therapeutic strategy that minimizes negative side 
effects. Over the last two decades, research has turned towards the development of 
alternative strategies of gene delivery vehicles in an effort to preserve the high 
efficiency of viral-based systems while minimizing dangerous side effects and concerns 
of the viral delivery vectors as questions regarding their safety in patients have 
emerged.  
1.2.2. Nonviral Vectors 
Avoiding carrier integration into the host genome, immunogenicity, and 
tumorigenicity are among the issues that are at the forefront of research aimed towards 
creating nonviral based carrier systems. In addition, viral-based systems are limited by 
the size of DNA they can carry [64, 77], are not easy to manufacture reproducibly [93], 
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and are more difficult to customize for targeting purposes [94]. Nonviral vectors are not 
derived from viral sources and thus may overcome many of the concerns associated 
with viral-based systems. There are numerous benefits for using nonviral delivery 
systems including nonimmunogenicity, nontumorgenicity, biocompatibility, the ability to 
target the carrier to particular cells/tissues by attaching ligands to the carrier surface, 
and others. In addition to these benefits, there is no restriction in the size of the DNA 
that can be delivered, which was a major negative associated with the use of viral-based 
vectors. Nonviral vectors can be classified into two major categories: lipid-based or 
polymer-based systems [95].  
1.2.2.1. Naked DNA-based Systems 
 The simplest method of nonviral delivery is the direct transfer of genes using 
plasmid DNA [96]. This method of gene transfer has been most successful when the 
DNA is injected directly into the tissue of interest, particularly in muscle tissue. Injection 
of naked plasmid DNA has been used to successfully express leptin and erythropoietin in 
muscle tissue [97], and even vascular endothelial growth factor to promote blood vessel 
development [98]. Because gene expression is generally low with this method, it has 
also been used to develop vaccines. Generating antiviral immune responses to 
infectious agents has led to the development of DNA vaccines against infectious 
diseases such as AIDS [99] and tumor vaccines that induce antitumor immunity by 
directly inhibiting tumor growth factor or eliciting an immune response [100]. However, 
gene expression is quite low using this method, likely because DNA is not protected 
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from degradation, and tissue diffusion is quite poor, limiting its application for gene 
therapy merely to delivery via direct intratissue injection.  
1.2.2.2. Lipid-Based Gene Carriers 
Lipid-based carriers are typically composed of neutral or charged lipids and can 
assume different organized structures including liposomes (Figure 1.1), emulsions, 
micelles, and others [97]. The earliest carriers were based on neutral or anionic 
liposomes which are generally nontoxic and fairly compatible with biological fluids, 
making them a good candidate for systemic delivery [97]. Neutral and anionic liposomes 
have been widely used for drug delivery applications [101] and early studies were able 
to establish the feasibility of using liposomes as a gene delivery vehicle [102]. 
Unfortunately, these liposomes were not successful as gene delivery carriers [97]. Since 
DNA is also negatively charged, encapsulation efficiency was very low [103]. In addition, 
these carriers lacked endosomal escape mechanisms and had insufficient interactions 
with cells, leading to low transfection. Because of technical difficulties associated with 
increasing DNA encapsulation within the vesicle, focus shifted towards cationic 
liposomes [97].   
Cationic liposomes have several advantages over neutral/anionic liposomes. 
Because of they are composed of lipids with a positively charged head group (Figure 1.2) 
they are able to complex with DNA through charge interactions instead of having to 



















Figure 1.2: Representative cationic lipid structure  
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During preparation, complexes can be formed such that the surface charge remains 
slightly positive, increasing interactions between the positively-charged complex and 
the negatively-charged cell membrane [97]. In addition, the composition of lipids can be 
selected such that the complex has a built-in endosomal escape mechanism which 
would increase DNA release into the cytosol after endocytosis [104]. Lastly, 
complexation between DNA and the cationic lipids may protect DNA from enzymatic 
degradation and physical damage [105]. Cationic liposomes can form different types of 
liposome/DNA complexes including spherical structures, rod-like structures, spherical 
aggregates, and compact nonaggregating particles [97]. However, the structure of 
liposome/DNA complexes can change over time and is affected by several factors 
including charge ratio between lipid and DNA, concentration, and solution pH. Cationic 
liposome/pDNA complexes can be administered using several different methods 
including intratumor injection [106], airway administration [107, 108], intraperitoneal 
administration [109], and intravenous administration [110]. Cationic liposomes have 
proven to be somewhat successful as gene carriers, and have been involved in gene 
therapy clinical trials for several types of cancer [111-117] and cystic fibrosis [118-121]. 
But transfer of functional DNA molecules into cells by DNA-loaded liposomes or 
virosomes is not very efficient. The difficulties involved with the intravenous use of 
cationic liposome-DNA complexes arise as a result of their underlying transfection 
mechanism. Cationic liposomes form complexes with the negatively charged DNA via 
charge interactions. Optimal transfection of the liposome-DNA complex relies on the 
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presence of excess positive charge, which is required for efficient interaction with the 
negatively charged cell membrane. Neutralization of excess positive charge in the 
liposome-DNA complex by negatively charged serum proteins may result in decreased 
transfection efficiency. Also, DNA might be released from liposome-DNA complexes by 
anionic molecules in the serum, rendering DNA more susceptible to enzymatic 
degradation. Furthermore, serum proteins can induce an aggregation of liposome-DNA 
complexes, leading to rapid clearance of liposome-DNA complexes from the blood by 
the reticuloendothelial system (RES). These problems, together with others, severely 
limit the intravenous application of cationic liposome-DNA complexes.  
1.2.2.3. Polymer-Based Gene Carriers 
 
Polymer-based systems have many appealing biological characteristics such as 
excellent biocompatibility, low immunogenicity, and no tumorigenicity that make them 
well-suited as a gene-carrier material. Other important characteristics include the ability 
to functionalize and customize polymers by adding features such as cell-targeting 
moieties, endosome-disrupting agents, and degradable architectures, allowing the 
flexibility to adapt polymer-based systems to suit any situation.  
The first reported use of polymer/DNA complexes for gene delivery by Wu et al. 
in 1988 where they administered polylysine/DNA complexes systemically and were able 
to detect gene expression in the liver [122]. Since that time many different polymers 
have been investigated including polyesters [123-127], poly-L-lysine (PLL) [128-133], 
poly(N-2-hydroxypropyl methacrylamide) (pHPMA) [134-137], and polyethyleneimine 
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(PEI) [138-141]. Polymer/DNA complexes (polyplexes) can assume various structures 
including toroidal structures [142, 143], spherical globules [144], small well-defined 
particles [145], nano- and microparticles [146, 147], and DNA-loaded polymeric 
microspheres [148]. The structure can vary depending upon the length and size of DNA, 
ionic strength of the solvent, and the concentration of the polymer and DNA during 
mixing. One method to avoid aggregation is to create cationic polymers with 
hydrophobic (hydrophilic) segments [149, 150]. Cationic polymers generally condense 
DNA more effectively than neutral polymers due to electrostatic interactions between 
the positively-charged polymer and negatively-charged DNA. Unlike liposomes where 
lipid selection is limited, the variety of polymers available is limitless as novel polymers 
can be designed to adapt to any situation with features including endosomal-disruption 
mechanisms [151], targeting moieties to increase cellular uptake, degradation 
mechanisms to decrease cytotoxicity, and others. Polymer vectors can be constructed 
either from degradable or nondegradable polymers and this selection varies according 
to the desired application of the vector.  
Polymeric micelle-based carrier systems and more specifically cationic-micelle 
systems have gained interest in recent years due to their unique core-shell architecture 
where hydrophobic segments segregate into an inner core surrounded by the 
hydrophilic shell or corona (Figure 1.3), and narrow size distribution. These charged 
micelles have high colloidal stability due to steric repulsion of their corona (shell) and 


































and the ability to modify the biological and physicochemical properties of the carrier by 
functionalizing the shell makes cationic micelles particularly attractive vehicles for gene 
delivery applications. The hydrophobic core has been used to load hydrophobic drugs 
such as paclitaxel whose use had been limited due to poor solubility in water; using 
micelle-based carrier systems shielded the drug from an aqueous environment and 
allowed higher local accumulation of the drug in the tissues of interest. Numerous 
studies have been conducted where the corona of the micelle was modified by binding 
ligands or other agents to increase targeted delivery of the carrier [153, 154], or 
creating polymers with stimuli-sensitive properties that can reduce side effects and 
increase therapeutic efficacy [154, 155].  
A major limitation in current nonviral vectors including polymer-based carriers is 
the low levels of cell transfection and gene expression compared to what viral-based 
vectors can achieve. Many combinations of existing and novel polymer systems have 
been investigated in an effort to increase cell transfection through a variety of 
mechanisms including increasing cellular uptake through targeting and prolonged 
systemic circulation, engineering endosomal escape mechanisms, and enhancing 
nuclear penetration. The most commonly studied cationic polymer systems include 
poly-L-lysine (PLL), poly(2-dimethylaminoethyl methacrylate) (PDMAEMA), 
polyamidoamine (PAMAM), and poly(ethylenimine) (PEI). These polymers have been 





transfection properties in vitro and in vivo [149, 156-161]. Numerous other types of 
cationic polymer systems have been investigated including various types of polyesters 
[123-126], polyurethanes [162, 163], and phosphor-containing polymers such as 
poly(phosphazenes) [164-166].  
1.2.2.4. Poly-L-Lysine (PLL)   
Poly-L-lysine (PLL) was the first cationic polymer to be studied for gene delivery 
(Figure 1.4). A targeted system directed towards hepatocytes was created by 
complexing PLL with asialoglycoprotein to form polyplexes. Since hepatocytes have a 
receptor for galactose-terminal asialo(glycoproteins), these complexes could be taken 
up into the cell via receptor-mediated endocytosis [167]. This system was also tested in 
vivo and showed preferential gene expression in the liver but no activity in other organs 




Figure 1.4: Chemical structure of poly(L-Lysine) (PLL)  
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receptor-mediated endocytosis and resulted in high levels of gene expression in human 
leukemic cells [168, 169]. Specific gene expression was observed in mouse lung 
endothelial cells using a PLL-antibody-DNA complex system which also targeted mouse 
lung tissue in vivo [170]. Although polylysine by itself is a very poor gene-delivery 
vehicle, conjugation with targeting ligands greatly increased its delivery efficiency both 
in vitro and in vivo. Since those initial studies, PLL has been used to transfect very 
diverse cell populations including tumor cells [171], pituitary cells [172], thyroid 
follicular cells [173], human blood monocyte-derived macrophages [174], and many 
others. Many studies regarding polyplex formation and endolysosomal escape were 
based on polylysine-DNA complexes. Due to its low transfection efficiency, and high 
toxicity, polylysine is generally used as a basis for comparison of more promising 
polymers. Some newer polymers derived from PLL are showing some promise as gene 
carriers including poly[a-(4-aminobutyl)-L-glycolic acid] (PAGA), a biodegradable 
polymer designed by Kim’s group [125, 175].  
1.2.2.5. Poly(amidoamine) (PAMAM) 
A second generation of polymeric gene carriers was developed based on 
poly(amidoamine) (PAMAM) dendrimers (Figure 1.5). PAMAM polymers have a large 
number of secondary and tertiary amines, allowing the polymer to act as a proton 
sponge [176]. PAMAM dendrimers form highly condensed complexes with DNA, and 
generally generation 6 or 7 dendrimers have been used for gene transfer [177]. 

















process has increased transfection efficiencies over nonactivated dendrimer systems 
[178]. Activated PAMAM dendrimers have been used to create two commercial 
transfection reagents by QIAGEN – SuperFect® Transfection Reagent and PolyFect® 
Transfection Reagent [177]. Both of these reagents have been used in laboratory gene 
transfer experiments to successfully transfect numerous cell types including primary 
aortic smooth muscle cells [179], neuronal cell lines [180], and fibroblast and epithelial 
cells [181]. Because of their generally good biocompatibility, nonimmunogenicity, and 
fairly high gene delivery efficiency [182-184], PAMAM dendrimers have been used in 
several gene therapy studies in vivo [185-187].   
1.2.2.6. Poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) 
Poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) is another well-studied 
cationic polymer that has shown promise as a gene carrier system (Figure 1.6). It has 
relatively low cytotoxicity, and its amine groups confer high buffering capacity to the 
polymer. The amine groups also allow the polymer to effectively bind and condense 
DNA to form discrete particles [188-192]. PDMAEMA can be conjugated to other 
polymers to create carriers which can serve dual purposes such as oligonucleotide 
delivery and bioimaging [193], or for combinatorial delivery by co-loading micelle 
carriers with both oligonucleotides and small chemical drugs [194]. This polymer has 
also been used to create temperature and pH-sensitive hydrogels for drug release in 





Cyclodextrins (CDs) are oligosaccharide molecules comprised of 6-8 glucose units 
linked together to form a ring with a hydrophilic exterior and a hydrophobic interior 
(Figure 1.7). There are several hydroxyl groups on the ring which can be used to  
manipulate the structure for different applications [196]. They have been used 
extensively in the pharmaceutical industry to improve the physical properties of drugs 
(stability, solubility, bioavailability) [197]. Two additional features also contribute to 
increased drug bioavailability; their membrane absorption enhancing properties and 
their ability to stabilize biomolecules by shielding them from nonspecific interactions in 
physiological media [198-200]. CDs have also been shown to increase oligonucleotide 
stability against endonucleases and can modulate undesirable side effects such as 
immune stimulation [201, 202]. The 7-glucose cyclodextrin in particular, termed β–
cyclodextrin (Figure 1.7), has been shown to increase gene expression in rat lung, which 
is attributed to enhanced membrane permeation capabilities in this tissue. In addition, 
these formulations showed no apparent toxicity in vivo [203].  
1.2.2.8. Polyethylenimine (PEI) 
To date, PEI remains as the gold standard for polymer-based carriers because it 
is able to achieve in vitro gene transfection rates comparable to those of viral vectors 
[204]. The high density of amino groups on the polymer gives it a high density of 


















to interact with negatively charged cells. The amino groups also act like “proton 
sponges” and endow the polymer with high buffering capacity inside the endosome  
[205, 206]. This leads to increased osmotic pressure and ion flux which in turn causes 
swelling and finally leads to endosome rupture. Membrane disruption can also occur 
through interactions between the positively charged PEI particles and the negatively 
charged endosomal membrane [160, 206, 207]. It has been shown that PEI can 
condense DNA to form small particles, and protects DNA from shearing or endosomal 
degradation to deliver intact DNA into cells [208]. PEI can be linear or branched and 
both forms are widely used because they provide high levels of gene expression (Figure 
1.8) [209]. PEI-based DNA particles have been used to treat bladder cancer in humans 
with encouraging results [210] and were able to produce permanent gene expression in 
the respiratory tract without undesirable expression in other tissues [211].  
One unfortunate drawback of highly positively charged polymers including PEI is 
they are quite cytotoxic, due to aggregation and reaction with erythrocytes and blood 
components in vivo [212, 213]. Because PEI is very effective in mediating gene delivery, 
several groups have focused their efforts towards altering PEI to increase its 
biocompatibility while maintaining its high tranfection rates. Direct modifications to PEI 
include acetylation by Forrest et al. to convert primary and secondary amines into 
secondary and tertiary amides, which increased gene delivery activity considerably over 














Figure 1.8: Structure of (a) linear and (b) branched polyethylenimine (PEI)   
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Layer-by-layer techniques emerged to better protect DNA from premature 
degradation after finding that low transfection rates correlated to exposed DNA in the 
complexes. While progress has been made in identifying favorable characteristics that 
enhance DNA packaging in the carrier, cellular uptake of the carriers, and DNA release 
once inside the cell, low levels of transfection and expression compared to what viral-
based carriers can achieve remains as a major limitation. One reason for lower efficiency 
is the number of extracellular and intracellular barriers encountered by the complex 
that need to be overcome to achieve successful transfection. Viral-based vectors are 
already equipped to deal with these barriers because the original virus had evolved 
coping mechanisms; however nonviral based carriers need to be designed to survive the 
barriers encountered.  
1.2.2.9. Polymeric Micelle-Based Systems 
 Micelles, particularly polymeric micelles, have gained popularity in recent years 
as a carrier system for delivering many different agents. Micelles have been used as 
carriers for diagnostic agents, improving aqueous solubility of hydrophobic drugs, and 
site-specific drug delivery. An attractive feature is the ability to customize the system by 
selecting polymers with particular features such as sensitivity to various stimuli like pH 
or light. Using amphiphilic molecules, molecules that contain both hydrophilic groups 
and hydrophobic groups, allows the self-assembly of micelles upon exposure to solvent. 
Amphiphilic copolymers can be formed by conjugating a hydrophilic or polar polymer to 
a hydrophobic or nonpolar molecule. Upon solvent exposure, these amphiphilic 
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copolymers spontaneously form micelles with a core-shell architecture (Figure 1.3). In 
an aqueous environment the hydrophobic blocks will aggregate together forming a core 
compartment away from the solvent, and the hydrophilic blocks will align towards the 
solvent and form a shell. This segregated compartment structure allows various poorly 
water-soluble molecules or drugs to be loaded into the core, increasing their solubility 
and bioavailability in the body. Advantages of using micelle-based systems include ease 
of preparation, increased circulation time, decreased toxicity, increased drug solubility, 
targetability, and enhanced penetration of tissue. The use of amphiphilic polymers in 
particular also minimizes micelle disintegration upon dilution and can potentially 
prolong drug delivery [215, 216]. Polymer options for the hydrophobic block include 
aspartic acid, propylene oxide, caprolactone, and L-lysine among others. Hydrophilic 
polymers include polyethyleneoxide, polyethyleneglycol, polyvinylalcohol, and 
polyethylenimine and others [217]. To date, micelle systems have been used to 
solubilize a myriad of poorly water-soluble drugs including diazepam [218], 
indomethacin [219], adriamicin [220-222], anthracycline antiobiotics [223], 
polynucleotides [224, 225], and doxorubicin [226].  
 Polymeric micelles have several benefits over other delivery systems such as 
microparticles and liposomes. Microparticles usually are micron-sized in diameter, so 
they are not suitable for many applications due to limited uptake in cells. In addition, 
they are not as effective at solubilizing poorly soluble drugs compared to micelle 
systems. Polymeric nanoparticles tend to aggregate easily, so although the actual 
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particle size may be less than 100nm, aggregation causes larger particles. They also have 
significant burst release due to the increased surface area in the formulation, and drug 
loading can be limited in these small particles.  
Micelle-based systems are more versatile than systems using polycation 
polymers alone. Micelle characteristics can easily be adapted to better suit a particular 
application by changing either block in a copolymer. For example, one can increase the 
capacity of the hydrophobic core by changing the hydrophobic block and thus better 
solubilize poorly soluble drugs [227-229]. Certain polymers contain charged groups that 
can cause endosomal disruption, leading to better delivery intracellularly [228].  
Polymeric micelles have also been used as gene delivery vehicles in an effort to 
develop more effective nonviral based delivery systems. If the hydrophilic block of a 
polymer is a cationic polymer such as polyethylenimine then the micelle can effectively 
condense negatively charged plasmid DNA (pDNA) into micelle/pDNA complexes 
(polyplexes). This protects the pDNA from degradation by enzymes or through 
hydrolysis until delivery. In addition, there is the option to modify the micelles with 
targeting ligands to increase site-specific accumulation or delivery. Using polycations 
alone to condense pDNA can result in uncontrollable biodistribution in the body 
because of their charge [230], increased cytotoxicity, and the polyplexes may also 
contain free polycations which can cause instability problems [206]. However, when 
pDNA is complexed with cationic micelles made from amphiphilic polymers, the 
resulting polyplexes are quite small (50-200nm) [152], soluble in aqueous solution, and 
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the repulsive nature of the corona prevents the aggregation of micelle particles, giving 
these systems high colloidal stability [152, 231]. During micelle preparation, any 
remaining free polymer is removed during the dialysis process, and the resulting 
micelles usually have lower cytotoxicity compared to their constituent polymers alone 
[231, 232]. DNA complexed with polymeric micelles to form polyplexes are protected 
from degradation by nucleases [231] and have reduced interaction with blood 
components during circulation [152]. An important benefit of using micelles as gene 
carriers is that gene expression can be higher and more sustained than is achieved with 
other delivery vehicles, which is especially true when micelles are equipped with 
targeting moieties which allow preferential accumulation at a site of interest [233, 234].  
1.3. Delivery Barriers 
Several obstacles must be overcome before successful transfection can occur. 
The first hurdles encountered are extracellular, during the delivery of the carrier to the 
host. Depending upon the route of administration, extracellular barriers can include 
polyplex stability during systemic circulation in the blood in vivo (or in cell culture 
medium for in vitro) and accumulation at nontarget sites or clearance by other 
mechanisms. For in vivo applications, there is the potential for the polyplex to become 
coated with serum proteins or DNA degradation from proteases in the blood which 
could decrease the efficacy of the polyplex. For in vitro applications polyplexes need to 
remain stable in the culture medium which contains serum proteins that can cause 
dissociation of the polyplex. Thus gene packaging and serum stability of the polyplexes 
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are very important. Cell-specific targeting can greatly enhance polyplex accumulation in 
the tissue or cells of interest.  
Once polyplexes are successfully internalized into the cell, they encounter 
intracellular barriers including escape from the endosomal compartment before being 
degraded, transport through the cytoplasm, and finally localization into the nucleus.  
Depending on the size of the polyplex, cell entry can occur by endocytosis and 
polyplexes are contained within endocytic vesicles known as endosomes. These 
endosomes can either shuttle their cargo back to the cell surface to be expelled via 
exocytosis or acidify and become lysosomes where polyplexes can be partially or 
completely degraded. Only DNA that is able to escape from the endosomes into the 
cytoplasm can be delivered to the nucleus. Endosomal escape can be mediated by 
conjugating pH-sensitive synthetic or fusogenic peptides to the polymer to disrupt the 
endosomal membrane, treating cells with buffering agents such as chloroquine which 
works for in vitro applications but would be unfeasible for in vivo applications, or by 
utilizing polymers known to have endosomolytic activity such as PAMAM and PEI.  
If endosomal escape is successful, polyplexes are released into the cytoplasm 
and must navigate their way to the nucleus. The concentration of proteins, cytosolic 
nucleases, other organelles, and the microtubule network within the cytoplasm present 
yet another barrier to efficient gene delivery. Current mechanisms of polyplex transport 
through the cytoplasm need to be properly characterized in order to properly design 
and improve polymeric vectors to overcome this obstacle. The final barrier to gene 
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transfection is entry into the nucleus through the double-bilayer nuclear membrane. 
Depending on how the polymer is designed, DNA delivery could occur once the entire 
polyplex enters the nucleus and the DNA is released inside the nucleus, or the polyplex 
could decomplex in the cytosol following endosomal escape so only the DNA is 
translocated into the nucleus.  
1.4. Nuclear Delivery 
 
Entry into the nucleus of a cell is highly controlled and occurs through tightly 
regulated pores. Molecules enter and exit the nuclear compartment only through these 
pores decorating the surface of the nuclear membrane. These pores are filled with 
assemblies called nuclear pore complexes (NPC). NPCs are assemblies comprised of 
about 30 different proteins that assemble to form a molecular mass approximately 50 
MDa in size [235]. The NPC is a cylindrical structure composed of eight spokes 
surrounding a central tube that connects the nucleoplasm to the cytoplasm [235]. The 
central channel has a minimum diameter of 35 nm and controls the entry and exit of 
molecules from the nuclear compartment. Molecules that are smaller than 35 nm in 
diameter (or less than 40 kDa) can freely diffuse through the nuclear pore complex; this 
includes small molecules such as water and oxygen, metabolites such as glucose, and 
ions [235-237]. Molecules larger than 35nm (or greater than 40 kDa) are unable to freely 
diffuse through the nuclear pore complex; instead they require a nuclear localization 




1.4.1. The Nuclear Pore Complex 
The nuclear pore complex (NPC) is a 50 MDa assembly comprised of 
approximately 30 different unique proteins that spans the nuclear envelope to connect 
the cytoplasm to the nucleoplasm. The NPC contains octagonal radial symmetry, with a 
main central core structure that is anchored into the nuclear envelope by eight spokes 
[235, 238]. The spokes join to form three main rings that surround a central tube. An 
inner ring (or central ring) is located in the middle of the NPC and is sandwiched by two 
outer rings, one on nucleoplasmic side and another on the cytoplasmic side. These rings 
together form the central tube around 35 nm in diameter through which transport 
occurs [235]. Peripheral filaments are attached to the core structure, filling the central 
hole and emanating into the nucleoplasm and cytoplasm. These filaments come 
together to form a basket-like structure on the nuclear side of the NPC [238].  
1.4.2. Nuclear Import 
All molecular entry into and out of the nuclear compartment occurs through the 
nuclear pore complexes. Entry can occur via two mechanisms, passive diffusion or 
energy-mediated transport. Small molecules such as ions and metabolites are freely 
permeable through the nuclear pores, while larger macromolecules require the 
assistance of nuclear transport factors and transport signals in order to enter or exit the 
nucleus [235, 238]. Nuclear transport factors bind to nuclear localization signals found 
on the cargo and then translocate through the nuclear pore. Translocation occurs in a 
three-step process. First, nuclear transport factors (NTF) recognize and bind to the 
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nuclear transport substrates. These NTFs include importin α and β, and RanGTP among 
others. Next, the NTF-cargo complex docks to the NPC by binding to filamentous Phe-
Gly nucleoporins and translocates through the NPC. Finally, after reaching its target 
compartment the NTF-cargo dissociates [235]. If molecules do not meet one of the 
aforementioned criteria, they are excluded from the nuclear compartment. This 
includes gene/polymer complexes, and is one of the reasons gene transfection using 
nonviral vehicles such as polymers remains low. An important factor for increasing 
transfection efficiency is to enhance delivery of polyplexes inside the nucleus of the cell. 
This can be accomplished by creating small polyplex particles which can easily diffuse 
through the nuclear pore, conjugating nuclear localization signals or nuclear proteins to 
the surface of the polyplex, or utilizing receptor-mediated transport by binding ligands 
to the polyplex such as glucocorticoids which cause translocation into the nucleus upon 
binding to the glucocorticoid receptor, thereby increasing accumulation in the nucleus 
and enhancing overall gene transfection.  
1.4.3. Glucocorticoid Receptors 
Glucocorticoid hormones are hydrophobic steroid hormones that are widely 
expressed in the cell [239, 240]. The binding of these molecules to the glucocorticoid 
receptor stimulate a number of profound physiologic effects many of which are 
necessary for life [241]. Every cell contains glucocorticoid receptors, and the binding of 
glucocorticoids to the receptor forms an activated ligand-receptor complex that 
translocates into the nucleus, and one result is the triggering of gene transcription and 
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expression [241]. In addition, it has been discovered that conjugating the particular 
glucocorticoid ligand dexamethasone to polymeric gene carriers such as 
polyethylenimine or polyamidoamine dendrimers caused an increase in gene expression 
that correlated to increased nuclear localization of the complexes [242]. 
Dexamethasone was even conjugated to DNA directly before transfecting cells and 
tested for its ability to increase gene expression. It was found that this Dex-DNA 
conjugate was increasingly localized in the nuclear compartment, and resulted in higher 
gene expression than when no dexamethasone was used. This indicates that 
dexamethasone directly increases the nuclear accumulation of DNA and could be 
beneficial for enhancing the nuclear accumulation of micelle/pDNA complexes.  
Dexamethasone is a steroid hormone (Figure 1.9) that after binding to the 
glucocorticoid receptor causes the nuclear pore complex to dilate followed by 
translocation into the nucleus [241, 243]. It has been suggested that the binding of 
glucocorticoid ligands such as dexamethasone to the glucocorticoid receptor may aid 
the entry of polyplexes into the nucleus by ligand-receptor-mediated transport. The 
presence of dexamethasone has been shown to facilitate the transport of polymer/DNA 
complexes into nucleus, and conjugating dexamethasone to the polymer increased 
transfection efficiency [242, 244]. By adding this molecule to polyplexes either by 
conjugation to the polymer backbone or by loading into the complex, transport of 





Figure 1.9: Dexamethasone 
 
that it may also suppress an immune response in the host, which could help decrease 
potential side effects resulting from the treatment. Because dexamethasone is a small 
hydrophobic molecule, it can easily be loaded into the hydrophobic core of a micelle 
creating a drug-loaded micelle, which can then be complexed with DNA to create a dual-
loaded carrier system.  
1.5 Clinical Needs – Formulation Stability During Storage 
 
From a therapeutic perspective, in addition to creating a gene delivery carrier 
that can transfect cells with high efficiency, the formulation must also be suitable for 
clinical applications. Important considerations include ease of administration, drug 
concentration, and stability of the formulation during long term storage. Many 
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formulations made from liposomes or polymer-based systems exist as colloidal liquids, 
which are generally stable for short periods of time [245]. However, some polymer 
systems are designed to be gradually degradable by hydrolysis so long-term storage in 
liquid form is not a viable option for these types of systems [246]. Additionally, many 
formulations can become unstable if kept in liquid form during long-term storage due to 
a variety of issues including degradation of the nonviral vector and/or drug [247], 
formation of insoluble aggregates [248], unwanted drug release [249], and loss of 
bioactivity [250]. One method to overcome the stability limitations of storing liquid 
formulations is to lyophilize the formulation, allowing storage in a powder formulation. 
When the formulation is required, it can be reconstituted though the simple addition of 
water or buffer.  While some success has been seen using this method, many groups 
have additionally added cryoprotective agents [251, 252] or modified the formulation in 
some way such as through PEGylation [253, 254] or physical cross-linking [255]. 
Unfortunately these formulations underwent changes in their characteristics following 
reconstitution such as increases in particle size [251]. The ideal scenario would be to 
have a formulation that can be lyophilized without using any special additives, 
reconstituted by simply adding water or buffer, and most importantly retain all of its 




1.6 Rationale for the Study 
Thus far, research has shown that gene therapy holds great promise as a 
therapeutic option for people suffering from diseases caused by mutated or absent 
genes. However, current gene vectors are derived from viruses which have raised many 
safety concerns due to harmful side effects such as immunogenicity and severe toxicity 
as seen with negative outcomes from several clinical trials. This has increased interest in 
nonviral carriers. Lipid-based carriers have been tested in several gene therapy trials but 
are plagued by limited DNA encapsulation and low transfection rates. Polymer-based 
gene carriers are a promising alternative delivery vehicle, because they avoid the 
negative issues associated with viral systems and polymeric micelle-based carriers using 
cationic polymers are particularly attractive because of their well characterized 
structure and drug loading capabilities. Long-term storage and utility of current gene-
carrier formulations in the clinic is also of concern because many systems cannot be 
stored long-term in aqueous form and attempts to lyophilize various formulations has 
uncovered difficulties in formulation integrity during lyophilization and following 
reconstitution.  
This study focuses on the creation of a reconstitutable cationic polymer micelle-
based gene delivery system that could be used as a dual delivery system and targeted to 
the nucleus of the cell. Three different PLGA-bPEI copolymer systems were investigated 
and compared to a control delivery system based on branched polyethylenimine 
bPEI25kDa alone. Although transfection efficiencies achieved using the copolymer systems 
38 
 
were slightly lower than levels achieved using bPEI25kDa alone, the copolymer systems 
were considerably less toxic than bPEI25kDa alone. Three different copolymer systems 
were used to make blank micelles and dexamethasone-loaded micelles that were 
characterized in terms of physicochemical and biological properties. 
Chapter 2 outlines the creation and evaluation of a reconstitutable charged 
polymeric micelle gene delivery system created from the copolymer (PLGA36kDa)2-b-
bPEI25kDa. The hypothesis was that this particular copolymer could form micelles and 
micelle/pDNA complexes that retained their physicochemical characteristics following 
lyophilization and reconstitution and these complexes could be used to successfully 
transfect cancer cells with an exogenous gene.  
Chapter 3 outlines the creation and evaluation of three different 
dexamethasone-loaded polymeric micelle systems with a PLGA-b-bPEI structure and 
their ability to enhance nuclear accumulation and gene expression in MCF7 cells. The 
hypothesis was that co-loading dexamethasone and complexation with pDNA would 
create a dual-delivery system. Following cellular uptake and endosomal escape, 
dexamethasone would release from the micelle core and dilate the nuclear pores, 
allowing increased entry and accumulation of polyplexes into the nucleus. This would 
increase gene transfection and subsequent gene expression, paving the way for more 
successful gene therapeutics delivery.  
Chapter 4 will summarize the scientific merits of the above studies and discuss 
some future directions for this research.  
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Finally, the appendix summarizes work completed on a prior dissertation project 
related to optimizing a bioartificial pancreas for the treatment of Type 1 Diabetes 
Mellitus. More specifically, insulin stimulating peptides were conjugated to a polymeric 
backbone and co-encapsulated with pancreatic islets in an alginate-poly-L-lysine 
microcapsule, and their potential to increase insulin output in response to elevated 
glucose levels was examined. Although this work is not directly tied to the main body of 
the dissertation, it is included in this dissertation for completeness.  
1.7. Specific Aims 
Combinational therapy is becoming more and more prevalent as a go-to method 
for treating many diseases including cancer [256-258]. Administering several 
medications together is often more beneficial than monotherapy approaches [259-261]. 
However, ensuring the delivery of all therapeutics to a target location is difficult, 
decreasing the overall effectiveness of the treatment. Co-delivery of agents 
simultaneously to a specific location would greatly enhance the efficacy of 
combinational therapy, and could mitigate side effects and potentially decrease the 
amount of drug necessary for treatment [262, 263]. I proposed to investigate the 
targeted delivery of two therapeutic agents simultaneously to the nucleus of a cell using 
a polymeric micelle carrier system.  
The micelle system will be a core-shell structure composed of the copolymer 
poly(DL-lactide-co-glycolide) and branched polyethyleneimine (PLGA-b-bPEI). The PLGA 
block will form the hydrophobic core region and the PEI block will form the hydrophilic 
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corona or shell region. Micelles should be internalized into the cell by endocytosis. PEI is 
well-known to have proton-buffering capacity and aid in endosomal escape due to the 
proton-sponge effect. Therapeutic agents can be loaded either into the hydrophobic 
core or bound to the hydrophilic shell of the micelle. Two different model therapeutic 
agents will be investigated: firefly luciferase reporter gene as a model gene drug, and 
dexamethasone as a model chemical drug. Dexamethasone is known to dilate nuclear 
pore complexes [264-266], and will be incorporated into the micelle core to facilitate 
increased nuclear delivery. Dexamethasone will be loaded into the core of the micelle 
during micelle formation by dialysis methods. The luciferase gene will be incubated with 
the drug-loaded micelles, allowing the gene to interact with the PEI corona layer and 
bind through electrostatic interactions, forming a micelle-gene complex. Thus, this core-
shell micelle structure can be used to simultaneously deliver different kinds of 
therapeutics to a target site.  
Aim 1: Demonstrate that two therapeutic agents can be loaded simultaneously into a 
PLGA-b-bPEI polymeric micelle carrier.  
a) Construction of the copolymer micelle system – The PLGA-b-bPEI copolymer will 
be synthesized, characterized and used to create the micelle carrier system for 
this study.  
b) Model therapeutic agents – The luciferase gene will serve as a model gene drug 
and the glucocorticoid analog dexamethasone will serve as the model chemical 
drug for this micelle carrier delivery system. 
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c) Drug loading – Dexamethasone will be loaded into the micelle core during 
micelle formation by dialysis. PLGA-b-bPEI polymer and dexamethasone will be 
mixed together in dimethyl sulfoxide and dialyzed against water to form the 
drug-loaded micelles. The luciferase gene will be loaded after micelle formation 
is complete. Micelles will be mixed with the gene and incubated together for 30 
minutes to allow for complexation to occur. These gene-micelle complexes will 
then be used for further studies.  
Aim 2: Prove that the polymeric carrier system co-loaded with dexamethasone and a 
gene is able to accumulate inside the nucleus of the cell and release its drug load within 
the nucleus and assess its potential efficacy by evaluating gene expression.  
a) Confirm nuclear accumulation of the carrier system – The presence of 
dexamethasone is known to have a dilatory effect on the nuclear pore complex 
which could aid in accumulation of the micelle carrier inside the nucleus. Once 
inside, gene transfection should occur. Accumulation of the carrier in the nucleus 
can be confirmed visually using fluorescence staining techniques and imaged 
using confocal microscopy.  
b) Confirm drug release within the nucleus – Gene drug delivery can be confirmed 
by evaluating gene expression. Comparing gene expression from micelles with 
dexamethasone versus without dexamethasone will indicate whether the drug is 




c) Confirm gene expression in breast cancer cells – Uptake of the micelle system 
should result in transcription and expression of the luciferase gene, which can be 
measured by a standard reporter gene assay normalized to total protein content 
in the cell. 
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This study investigated the potential of creating a charged polymeric micelle-
based nucleic acid delivery system that could easily be reconstituted by the addition of 
water. (PLGA36kDa)2-b-bPEI25kDa (PLGA MW 36 kDa, bPEI Mw 25 kDa, PLGA:bPEI block ratio 
= 2) was synthesized and used to prepare cationic micelles. The copolymer retained 
proton-buffering capability from the bPEI block within the endosomal pH range. 
Micelle/pDNA complexes retained their particle size (100-150 nm) and zeta potential 
(30-40 mV) following reconstitution. It was found that adding a small amount of low 
molecular weight bPEI (1.8 kDa) completely shielded pDNA in the micelle/pDNA 
complexes and enhanced transfection efficiency 50-100 fold for both fresh and 
reconstituted complexes without affecting complex size. Transfection efficiency for 
“reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) complexes was 16-fold higher than its 
“fresh” counterpart. Although transfection levels achieved using “reconstituted” 
micelle/pDNA/bPEI1.8kDa complexes were 3.6-fold lower than control “fresh” 
bPEI25kDa/pDNA (N/P 5) complexes, transfection levels were 39-fold higher than 
                                                     
∗ Portions of the text and figures are reproduced with kind permission from Mishra D, Kang HC, and Bae 
YH. Reconstitutable charged polymeric (PLGA)2-b-PEI micelles for gene therapeutics delivery. Biomaterials 
2011; 32(15):3845-54. (in press) Copyright 2011 Elsevier Ltd.  
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“reconstituted” bPEI25kDa/pDNA (N/P 5) complexes. The micelle/pDNA/bPEI1.8kDa system 
showed very low cytotoxicity in MCF7 cells even with pDNA doses up to 20 µg, and 
transfection levels increased linearly with increasing pDNA dose. These results indicate 
that this PLGA-b-bPEI polymeric micelle-based system is well suited as a reconstitutable 
gene delivery system, and has high potential for use as a delivery system for gene 
therapy applications.  
2.2. Introduction 
Gene therapy is a technique that uses genes to treat or prevent disease. There 
are several applications for gene therapy including replacing a mutated gene with a 
healthy copy of gene [1, 2], introducing a new gene to help fight disease [3, 4], or 
inactivating a mutated gene that is not functioning correctly [5]. This technique has the 
potential for broad scale application and impact in treating both acquired and inherited 
diseases. Although there has been some success using viral vector systems as vehicles 
for gene transfection in vitro and in vivo, the large number of drawbacks associated with 
viral-based carrier systems has increased interest in the development of nonviral 
delivery systems [6]. Concerns about the integration of delivered exogeneous DNA into 
the host genome [7-9], cytotoxicity [10], tumorigenicity [11], and immunogenicity [12] 
have increased interest in finding alternative delivery systems [6, 13]. 
Nonviral based delivery systems are typically classified into two main categories 
– lipids and polymers. With attractive biological traits such as low immunogenicity, no 
tumorigenicity, and excellent biocompatibility, polymer-based systems offer the ability 
to engineer carrier systems with customized features that can be adapted to suit any 
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system [6]. Functionalities include attaching targeting moieties to the nonviral polymer 
carrier for targeting specific cell types [14-16], adding endosomolytic agents to disrupt 
the endosome [17, 18], increasing nuclear delivery by targeting the cell nucleus [19, 20], 
or designing degradable polymers to decrease toxicity [21-23]. 
Many different combinations of polymeric/oligomeric blocks in single polymer 
systems have been created and studied in an effort to increase utility [24]. Block 
copolymer micelle systems in particular have gained interest in recent years as 
promising drug delivery vehicles because of their ability to prolong circulation in the 
blood and their ability to modulate the pharmacokinetics of drugs [25]. For gene 
delivery, micelle copolymers having a hydrophobic block-charged hydrophilic block 
architecture usually assemble into a core-shell micelle structure, creating the potential 
to load hydrophobic drugs and gene drugs into the different compartments (core and 
shell), respectively. Some recent examples of such copolymers include poly(ε-
caprolactone)-bPEI1.8kDa [26], poly((N-methyldietheneamine sebacate)-co-[(cholesteryl 
oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate) [27], and 
poly(dimethylaminoethyl methacrylate)-poly(ε-caprolactone)-poly(dimethylaminoethyl 
methacrylate) [28].  
Even so, nonviral systems are still a long way from being readily available as a 
mainstream therapeutic option. Some important formulation considerations for clinical 
usage are drug concentration [29], ease of administration [30], and formulation stability 
during storage [31, 32]. Many formulations made from liposomes or polymer-based 
systems exist as colloidal liquids, which are generally stable for short periods of time 
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[33]. However, some polymer systems are designed to be gradually degradable by 
hydrolysis so long-term storage in liquid form is not a viable option for these types of 
systems [34]. In addition, many formulations can become unstable if kept in liquid form 
during long-term storage due to a variety of issues including degradation of the nonviral 
vector and/or drug [35], formation of insoluble aggregates [36], unwanted drug release 
[37], and loss of bioactivity [38]. One method to overcome the stability limitations of 
storing liquid formulations is to lyophilize the formulation, allowing storage in a powder 
form. When the formulation is required, it can be reconstituted though the simple 
addition of water or buffer.  While some success has been seen using this method, many 
groups have additionally added cryoprotective agents [39, 40] or modified the 
formulation in some way such as through PEGylation [41, 42] or physical cross-linking 
[43]. Unfortunately these formulations showed some changes in their characteristics 
following reconstitution such as increases in particle size [39]. The ideal scenario would 
be to have a formulation that can be lyophilized, be reconstituted easily by simply 
adding water or buffer, and most importantly retain its original chemical, physical and 
biological properties.   
This study was designed to investigate the possibility of creating a charged 
polymeric micelle-based gene therapeutic delivery system that maintains efficacy 
following lyophilization and reconstitution. Branched polyethyleneimine (bPEI) and 
poly(lactide-co-glycolide) (PLGA) were selected to create our micelle system. The 
hydrophilic cationic component bPEI25kDa (Mw 25 kDa) has been used as the gold 
standard for polymeric vectors but its viscosity and sticky characteristics have limited its 
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use in a dried state. The hydrophobic degradable component PLGA has been used in 
dried nano/microparticles form but its water-insolubility limits its use for creating 
formulations containing biological therapeutics in aqueous buffers. In order to extract 
the favorable features from both bPEI25kDa and PLGA36kDa, these two polymers were 
chemically linked together and the resulting block copolymer was used to create 
charged micelles which could interact with biological agents in aqueous solution and 
could also be stored as a dried formulation. Physicochemical and biological comparisons 
between freshly-prepared micelle-based gene complexes and reconstituted micelle-
based gene complexes were evaluated in terms of particle size, zeta potential, pDNA 
condensation ability, and cell transfection efficiency.  
2.3. Materials and Methods 
2.3.1. Materials 
Poly(lactide-co-glycolide) (PLGA36kDa; Resomer®503H; lactide:glycolide = 1:1 
(mole/mole); approximate MW 36 kDa) having a carboxylic group at one end was 
purchased from Boehringer Ingelheim Pharm GmbH & Co. KG (Germany). Two bPEIs 
having Mr 1.8 kDa (bPEI1.8kDa) and Mw 25 kDa (bPEI25kDa; Mn 10 kDa) were purchased 
from Polysciences, Inc. (Warrington, PA) and Sigma-Aldrich Co. (St. Louis, MO) 
respectively. Triethylamine (TEA), N,N’-dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide (NHS), RPMI1640 cell culture medium powder, sodium bicarbonate, 
D-glucose, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt (HEPES), 
human recombinant insulin, Ca2+-free and Mg2+-free Dulbecco’s phosphate buffered 
saline (DPBS), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), 
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dimethyl sulfoxide (DMSO), and agarose were purchased from Sigma-Aldrich Co. (St. 
Louis, MO). Fetal bovine serum (FBS), penicillin/streptomycin, and 0.25% trypsin/EDTA 
were purchased from Gibco BRL (Grand Island, NY). YOYO-1 dye was purchased from 
Invitrogen, Inc (Carslbard, CA). Ethidium bromide (EtBr) and the Biocinchoninic Acid 
Protein Assay Kit (BCA) were obtained from Thermo Fisher Scientific, Inc. (Waltham, 
MA). Luciferase assay kit was obtained from Promega Co. (Madison, WI). Spectrapor 
dialysis membrane MWCO 15 kDa was purchased from Spectrum Laboratories, Inc. 
(Rancho Dominguez, CA). Plasmid DNA (pDNA) encoded with the firefly luciferase 
reporter gene (gWiz-Luc) was purchased from Aldevron, Inc. (Fargo, ND). 
2.3.2. Cell Culture 
In this study, MCF7 cells (human breast adenocarcinoma cell line) were used for 
determining the cytotoxicity of micelles and polyplexes and for polyplex transfection. All 
experiments used MCF7 cells cultured in RPMI1640 cell culture medium supplemented 
with insulin (4 mg/L), glucose (2 g/L), 10% heat-inactivated fetal bovine serum (FBS) and 
1% penicillin/streptomycin antibiotics at 37 °C in humidified air containing 5% CO2. 
2.3.3. Synthesis and Characterization of Amphiphilic Block Copolymers 
A block copolymer composed of PLGA36kDa and bPEI25kDa ((PLGA36kDa)2-b-bPEI25kDa) 
was synthesized by conventional condensation between the carboxylic acid group from 
PLGA36kDa and the amine groups from bPEI25kDa as shown in Fig. 2.1(a). In detail, 
PLGA36kDa (100 µmol) and bPEI25kDa (50 µmol) were dissolved separately in DMSO (100 
mL) and stirred independently for 4 hours. Then the two polymer solutions were mixed 
72 
 
together along with DCC (1 mmol), NHS (1 mmol), and TEA (0.1 mL) and polymerization 
was carried out at room temperature (RT) for 48 hours under constant stirring. About 
100 mL of deionized (DI) water was added to the reaction mixture and stirred for 2 
hours; then the polymer solution was transferred to a dialysis tube (MWCO 15 kDa) and 
dialyzed against DI water for two days to remove any unreacted bPEI25kDa. Unreacted 
PLGA36kDa was removed by filtration at a later stage following micelle formation. The 
dialysis solution was lyophilized to obtain the resulting block copolymer. The chemical 
structure was confirmed by 1H-NMR spectroscopy.  
 2.3.4. Preparation and Characterization of Micelles  
Micelles were prepared using standard dialysis techniques. As shown in Fig. 
2.1(b), (PLGA36kDa)2-b-bPEI25kDa was dissolved in DMSO at a concentration of 10 mg/mL 
and stirred for 4 hours at RT. HEPES buffer (20 mM, pH 7.4) was added to the reaction 
mixture at an equivalent volume to DMSO and stirred for an additional 2 hours. The 
reaction mixture was transferred to a dialysis membrane (MWCO 15 kDa) and dialyzed 
against DI water for 24 hours. The resulting micelle solution was filtered using a 0.22 µm 
filter to remove any unreacted PLGA36kDa remaining from the synthesis (which 
precipitates in water) and the remaining solution was lyophilized and stored at -20°C 
until needed. 
Particle size and zeta potential of freshly-prepared micelles and reconstituted 
micelles were measured in HEPES 20mM buffer at RT using a Zetasizer 3000HSA 
(Malvern Instruments Inc., Worcestershire, UK) with a fixed wavelength of 677 nm and a 







Figure 2.1: Synthesis of PLGA-b-bPEI copolymer and schematic of micelle 




























Figure 2.1 continued: (b) schematic representation of {PlGA36kDab-b-bPEI25kDa micelles, 
micelle/pDNA complexes, and micelle/pDNA/bPEILMW complexes. 
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To evaluate whether the (PLGA36kDa)2-b-bPEI25kDa micelles maintained any proton 
buffering capacity from the bPEI25kDa block, micelles were titrated using traditional acid- 
base titration methods [18, 23]. (PLGA36kDa)2-b-bPEI25kDa micelles were dispersed in a 
fixed volume of 150 mM NaCl and titrated from pH 7.4 to pH 3 using 0.1 N HCl. The 
proton buffering ability of the (PLGA36kDa)2-b-bPEI25kDa micelles was compared to 
bPEI25kDa alone within the pH range 7.4-5.1 because this pH range correlates with typical 
endolysosomal pHs. Buffering capacity (%) of the polymers was calculated using the 
following equation [44]: 
 
where ∆VHCl is the volume of the HCl solution (0.1 M) which decreased the pH value of 
the polymer solution from pH 7.4 to pH 5.1, CHCl is the concentration of the HCl solution 
(0.1 M), and N is the total moles of protonable amine groups contained in the polymer. 
Cytotoxicity of (PLGA36kDa)2-b-bPEI25kDa micelles was assessed using standard 
protocols for MTT-based cell viability assay [18, 23]. MCF7 breast cancer cells were 
seeded in a 96-well plate at a density of 5000 cells/well in culture medium (0.1 mL). 
Sample solutions (10 µL) at various concentrations were added to each well and 
incubated for 24 hours. MTT solution (10 µL, 5 mg/mL) was added to each well and the 
plates were incubated for 4 hours at 37°C in a cell culture incubator. Media was 
completely removed, 100 µL of DMSO was added to each well to dissolve the formazan 
metabolites, and the plate was incubated for 10 minutes at 37°C. Absorbance was 
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measured at 570 nm using a microplate reader (SpectraMax® M2, Molecular Devices, 
Sunnyvale, CA) and used to calculate cell viability.  
2.3.5. Preparation and Characterization of Polyplexes 
Micelle solutions prepared by standard dialysis techniques and used immediately 
are referred to as “fresh” micelles. “Fresh” micelles that were lyophilized and then 
reconstituted by adding DI water are referred to as “reconstituted” micelles. Micelle 
solutions (fresh or reconstituted) were mixed with pDNA in HEPES buffer (20 mM, pH 
7.4) containing 5% glucose (HBG) and incubated at RT for 30 minutes to form polyplexes. 
Some polyplexes were additionally mixed with a small amount of bPEI1.8kDa following 
complexation at a weight ratio of 2.5µg bPEI1.8kDa per 1µg pDNA. This method was used 
to create polyplexes for particle size and zeta potential measurements, gel retardation 
studies, gene transfection and cell viability tests.  
Complexation between micelles and pDNA was evaluated by gel retardation and 
dye quenching methods [16, 18]. For the gel retardation studies, polyplex solution (0.5 
μg pDNA in 10 μL) was loaded onto a 0.8 % agarose gel containing ethidium bromide 
(EtBr) (100 ng/mL). Electrophoresis was run using 0.5X Tris-buffer containing boric acid 
and EDTA (TBE) at 100 V for 60 minutes. The gel was imaged using an Alpha Innotech 
FluorChem FC2® instrument with Alpha View Software (Cell Biosciences, Santa Clara CA).  
For the dye quenching assays, pDNA was mixed with EtBr at a mole ratio of five 
nucleotides per one EtBr and pre-incubated in the dark at RT for 30 minutes. Using EtBr-
intercalated pDNA, polyplexes were prepared following the same method described 
above. Polyplexes were excited at 515 nm and the emitted fluorescence was measured 
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at 595 nm using a Spectramax® M2 spectraphotometer (Molecular Devices, Sunnyvale 
CA).  
Particle size and zeta potential of fresh polyplexes and reconstituted polyplexes 
were measured at RT using a Zetasizer 3000HSA (Malvern Instruments Inc., 
Worcestershire, UK) with a fixed wavelength of 677 nm and a constant angle of 90°.  
In vitro transfection of fresh polyplexes and reconstituted polyplexes was 
evaluated in MCF7 cells using previously reported methods [45]. The cells were seeded 
at a density of 5 × 105 cells/well in 6-well plates and cultured for 24 hours in culture 
medium (2 mL). One hour prior to transfection, the cell culture medium was removed 
and replaced with serum-free insulin-free culture medium (2 mL). Polyplexes were 
added to the wells (20 µL volume, pDNA content was fixed at 1 µg/well) and cells were 
incubated for 4 hours at 37°C. The medium was replaced with the complete culture 
medium (supplemented with serum and insulin) and incubated for another 44 hours. 
Following incubation, culture medium was removed and cells were rinsed once with 
DPBS and lysed using a reporter lysis buffer. Luciferase gene expression (relative 
luminescence units (RLU)) was quantified by following the manufacturer’s protocol for 
the luciferase assay. Protein content in the cells was evaluated by the BCATM protein 
assay. Gene transfection efficiency is reported as RLU/mg protein.  
In vitro cytotoxicity of fresh polyplexes and reconstituted polyplexes with or 
without bPEI1.8kDa was monitored by MTT-based cell viability assay. The experimental 
procedure was the same as previously described for in vitro transfection except the cell 
number used (2.5×105 cells/well; 12-well plates) and the polyplex dose (10 µL; 0.5 µg 
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pDNA/well). After completing the 48-hour transfection procedure, MTT solution (0.1 mL; 
5 mg/mL) was added to the cells (in 1 mL of culture medium). After an additional 4-hour 
incubation, the MTT-containing medium was removed. The resulting formazan crystals 
produced by living cells were dissolved in 1 mL of DMSO and absorbance was measured 
at 570 nm using a microplate reader. 
For the pDNA dose-dependent transfection and cytotoxicity studies, the final 
glucose concentrations of transfection media and culture media with polyplex solutions 
were adjusted to 2 g/L to avoid any potential glucose-induced effects on cell 
viability/toxicity.  
Cellular uptake of the polyplexes was monitored using flow cytometry following 
methods described elsewhere [23]. Briefly, polyplexes were prepared using pDNA 
stained with YOYO-1 dye and added to cells preseeded in 6-well culture plates. After 
incubation for 4 hours, cells were detached and fixed with 4% paraformaldehyde 
solution. Flow cytometry (FACScan Analyzer, Becton-Dickinson, Franklin Lakes, NJ) was 
used to monitor cells containing fluorescence and a primary argon laser (488nm) and 
fluorescence detector (530 ± 15nm) were used to detect the presence of YOYO-1 dye. 
The number of YOYO-1 stained-pDNA molecules contained per cell was counted and 
reported per event.  
The statistical significance of the data was evaluated by conducting unpaired 
Student’s t-test with a confidence level of p<0.05, one-variable analysis of variance 




2.4. Results and Discussion 
2.4.1. Synthesis and Characterization of (PLGA36kDa)2-b-bPEI25kDa  
Block Polymers 
Cationic amphiphilic block copolymers composed of PLGA36kDa and bPEI25kDa were 
synthesized by a conjugation reaction between monocarboxylated PLGA36kDa and the 
primary amines of bPEI25kDa (Fig. 2.1(a)). Copolymer synthesis and block ratio (PLGA36kDa 
to bPEI25kDa) were confirmed by 
1H-NMR. In d6-DMSO, (PLGA36kDa)2-b-bPEI25kDa polymer 
was confirmed by observing peaks centered around δ=5.20 for C(=O)-CH2-O of glycolide, 
δ=1.45 for CH3- of lactide, δ=4.85 for C(=O)-CH(CH3)-O  of lactide, and δ= 3.35, 3.80, and 
4.10 for the -CH2- groups neighboring the primary, secondary, tertiary amines of 
bPEI25kDa (Fig. 2.2). However, the -CH2- groups of bPEI25kDa showed broad absorption due 
to the overlapping absorption of the amine groups of bPEI25kDa [46] as seen in Fig. 2.2. In 
addition, the ratio of lactide and glycolide in (PLGA36kDa)2-b-bPEI25kDa from the spectra 
taken in DMSO did not match the original 1:1 mole ratio contained in the PLGA36kDa. This 
could be due to the weakly soluble character of bPEI25kDa in DMSO; some fraction of the 
lactide and glycolide could have been hidden from detection by the bPEI25kDa domain.  
Thus, to obtain accurate block ratios for (PLGA36kDa)2-b-bPEI25kDa, the PLGA36kDa 
block was completely degraded into its glycolic acid and lactic acid units by base-
catalyzed hydrolysis in D2O containing 1 N NaOH. The degradation products of 
(PLGA36kDa)2-b-bPEI25kDa were very soluble in the aqueous solution. Based on the 
integration ratio of glycolic acid (or lactic acid) and bPEI25kDa (Fig. 2.3), the block ratio of 

































Figure 2.3: 1H-NMR spectra of hydrolyzed (PLGA36kDa)2-b-bPEI25kDa  




data) was approximately 79.5 kDa based on Mn (~94.5 kDa based on Mw). Therefore, as  
designed, the block copolymer is very close to a triblock copolymer of PLGA36kDa-b-
bPEI25kDa-b-PLGA36kDa ((PLGA36kDa)2-b-bPEI25kDa).  
2.4.2. Preparation and Characteristics of (PLGA36kDa)2-b-bPEI25kDa Micelles 
Utilizing the amphiphilic character of the block copolymer, positively-charged 
polymeric micelles were formed using conventional dialysis methods (Fig. 2.1(b)). The 
micelles formed a core-shell structure where PLGA36kDa formed the core and bPEI25kDa 
formed the corona (or shell). Cationic micelles made from (PLGA36kDa)2-b-bPEI25kDa had 
an average diameter of 50-60 nm (Zavg-particle size relevant to hydrodynamic size) and 
zeta potential of 15-25 mV (Fig. 2.4). Cationic micelles in aqueous solution maintained 
their size and zeta potential because the strong positively-charged corona prevented the 
formation of aggregated micelles due to repulsion. The micelle core made from 
relatively high molecular weight PLGA (MW 36 kDa) can be characterized by strong 
hydrophobicity [47-49] and slow degradation rate [47, 50, 51].  
Although the aqueous colloidal stability of (PLGA36kDa)2-b-bPEI25kDa micelles can be 
assured for up to 4 days when stored at 4°C, long-term exposure to various storage 
conditions (humidity, temperature, aqueous solution, etc.) may alter the 
physicochemical characteristics (particle size and zeta potential) of the micelles and 
could damage the biological function of any biotherapeutic agents loaded into the 
micelles. Storage in a powder form could alleviate the potential pitfalls associated with 









Figure 2.4: Particle size and zeta potential of (PLGA36kDa)2-b-bPEI25kDa micelles  
before and after reconstitution. (n=5; mean ± SD)  
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monitored to evaluate whether the colloidal stability of the micelles was preserved after 
lyophilization. As shown in Fig. 2.4, particle size and zeta potential of reconstituted 
micelles were similar to those of fresh micelles.   
It is well known that bPEI25kDa has very strong proton-buffering capabilities. To 
determine how much proton-buffering capacity was preserved in the (PLGA36kDa)2-b-
bPEI25kDa micelles, (PLGA36kDa)2-b-bPEI25kDa (5 mg/mL; 43.88 µmol of amines in 3 mL) was 
dissolved in 150 mM NaCl and titrated from pH 7.4 to pH 3.0 by adding 0.1 N HCl. The 
buffering capacity of the copolymer was compared to bPEI25kDa at 0.5 mg/mL (34.88 
µmol of amines in 3 mL) and 0.75 mg/mL (52.33 µmol of amines in 3 mL) because the 
weight percent of bPEI25kDa in the copolymer was approximately 12.6% (based on Mn). 
As shown in Fig. 2.5, the (PLGA36kDa)2-b-bPEI25kDa copolymer retained broad proton 
buffering ability within the endosomal pH range (specifically pH 5.1 to pH 7.4) similar to 
bPEI25kDa, although the buffering capacity (10.6%) was lower after copolymerization as  
compared to free bPEI25kDa (average 17.2% from two different concentrations). The 
reason for this decrease is most likely because there is decreased accessibility of protons 
to protonate secondary or tertiary amines located near the linkage to the strong 
hydrophobic PLGA block which prevents them from becoming ionized as effectively 
following polymerization, thus reducing the overall buffering capability.    
The toxicity of the polymeric micelles was compared to the toxicity of control 
polymers (i.e., bPEI25kDa and bPEI1.8kDa) as shown in Fig. 2.6. As expected, the cytotoxicity 
of the micelles was quite low compared to bPEI25kDa alone. The IC50 of (PLGA36kDa)2-b-
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However, if the weight fraction of bPEI25kDa contained in the copolymer is considered, 
then the IC50 of PEI25kDa in (PLGA36kDa)2-b-bPEI25kDa (13.9 µg/mL) is not significantly 
different from bPEI25kDa alone. In addition, the cytotoxicity contribution from bPEI1.8kDa 
was negligible within the concentration range used in the transfection studies (2.5 µg 
per 1 µg pDNA; 1.25-25 µg/mL bPEI1.8kDa for 1-20 µg pDNA), with cell viabilities higher 
than 90% for the concentrations of bPEI1.8kDa used.  
2.4.3. Preparation and Characteristics of (PLGA36kDa)2-b-bPEI25kDa  
Micelle-Based Polyplexes 
Reconstituted (PLGA36kDa)2-b-bPEI25kDa micelles were complexed with pDNA and 
characterized to further address whether (PLGA36kDa)2-b-bPEI25kDa micelle/pDNA 
complexes (abbreviated as micelle/pDNA complexes) could be used to produce 
exogenous proteins in cells via transfection of exogenous therapeutic pDNA. To evaluate 
this potential, the first step was to form electrostatic complexes between cationic 
micelles and anionic pDNA. Although most pDNA appeared to complex with the micelles 
at low weight ratios (WR) of micelle to pDNA (e.g., WR <3), some pDNA remained 
uncomplexed (Fig. 2.7). With higher WRs (e.g., WR 25), all of the pDNA complexed with 
the micelles but some pDNA still appeared to be exposed or only weakly complexed (Fig. 
2.8). Nevertheless, micelle/pDNA complexes having WR ≥ 15 were approximately 50-
120 nm in diameter and had a strong positive zeta potential (20-25 mV) (Fig. 2.9). When 
micelle/pDNA complexes with WR 15-30 were used to transfect MCF7 cells, the 
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than bPEI25kDa/pDNA complexes (N/P 5) (Fig. 2.10). This result may be due to either 
weak complexation between pDNA and the micelles or the presence of partially 
exposed pDNA on the surface of the micelle/pDNA complexes. 
To solve the aforementioned possible issues with micelle/pDNA complexes, low 
molecular weight (LMW) bPEIs were introduced into the micelle/pDNA complexes. LMW 
bPEIs could shield any exposed pDNA on the surface of the complexes through 
electrostatic layer-by-layer (LBL) attraction. In addition, LMW bPEIs could fill up any free 
volume between the cationic micelles and pDNAs and induce tighter complexation. 
From among the commercially available bPEIs, the lowest MW bPEI (i.e., bPEI0.8kDa) was 
selected as the first candidate to prove these hypotheses. However, micelle/pDNA 
complexes shielded with bPEI0.8kDa (micelle/pDNA/bPEI0.8kDa complexes) still had some  
exposed pDNA, as illustrated by the detection of EtBr-intercalated pDNA from those 
complexes in the gel retardation data (Fig. 2.11). The next smallest available bPEI 
(bPEI1.8kDa) was selected next to see if it could endow stronger interaction between the 
LMW bPEIs and pDNA. Introducing bPEI1.8kDa resulted in no detection of EtBr-
intercalated pDNA in “fresh” micelle/pDNA/bPEI1.8kDa complexes (Fig. 2.7(a)). In addition, 
dye quenching results clearly indicate that bPEI1.8kDa completely prevented pDNA 
exposure on polyplex surface (Fig. 2.7(b)). These findings indicate that bPEI1.8kDa 
completely shielded any exposed pDNA on the surface of “fresh” micelle/pDNA 















Figure 2.11: Surface shielding of micelle/pDNA complexes with 5 µg of bPEI0.8kDa. 
Micelle/pDNA complexes were prepared using 1 µg of pDNA. (n = 3; mean + SD) 
 
Particle size and zeta potential of “fresh” micelle/pDNA complexes and “fresh” 
micelle/pDNA/bPEI1.8kDa complexes were further investigated to address whether 
bPEI1.8kDa mainly affected the surface shielding on the micelle/pDNA complexes or 
induced tighter complexation in the micelle/pDNA complexes. As shown in Fig. 2.12, the  
particle sizes of “fresh” micelle/pDNA complexes and “fresh” micelle/pDNA/bPEI1.8kDa 
complexes were not significantly different. This finding indicates that the major effect of 
bPEI1.8kDa treatment is probably not the induction of tighter complexation. However, the 
introduction of bPEI1.8kDa strongly increased the zeta potential to more positive values 
(30-40 mV) compared to micelle/pDNA complexes where the pDNA was fully exposed 




























at WR 3 to 5). These results may indicate that bPEI1.8kDa bound to and protected any 
pDNA exposed on the surface of micelle/pDNA complexes. 
After examining the physicochemical similarities between “fresh” micelles and 
“reconstituted” micelles, the effects of reconstitution on polyplexes were characterized 
in terms of complexation, particle size, and zeta potential. Although EtBr-intercalated 
pDNA was detected for “fresh” micelle/pDNA complexes (WRs 4-5), EtBr-intercalated 
pDNA was not detectable for “reconstituted” micelle/pDNA complexes (WRs 4-5) (Fig. 
2.7). It is possible that the lyophilization process may decrease the distance between 
phosphate groups in the pDNA and the primary amines of bPEI25kDa corona and thus 
further increase their electrostatic attraction. These tighter interactions could then 
prevent EtBr from intercalating with pDNA. However, in the case of bPEI1.8kDa-shielded 
micelle/pDNA complexes, there was no apparent lyophilization effect because the 
polyplexes (WRs 1-5) had completely shielded pDNA regardless of whether the 
polyplexes were “fresh” or “reconstituted” (Fig. 2.7). Monitoring particle size of the 
polyplexes confirmed that the lyophilization and reconstitution process did not 
significantly affect particle size of “reconstituted” polyplexes compared to “fresh” 
polyplexes regardless of whether they were bPEI1.8kDa-shielded or unshielded 
micelle/pDNA complexes (Fig. 2.12). In addition, the zeta potential of “reconstituted” 
polyplexes was not significantly different from “fresh” polyplexes (Fig. 2.12). These facts 
support the theory that the lyophilization and reconstitution of polyplexes may not 
negatively impact the physicochemical characteristics of “fresh” polyplexes.  
96 
 
2.4.4. Biological Characteristics of (PLGA36kDa)2-b-bPEI25kDa  
Micelle/pDNA/bPEI1.8kDa Complexes 
Transfection experiments using micelle/pDNA/bPEI1.8kDa complexes were 
performed in MCF7 breast cancer cells, using bPEI25kDa/pDNA (N/P 5) complexes as a 
control. As shown in Fig. 2.13, transfection efficiencies for “fresh” 
micelle/pDNA/bPEI1.8kDa complexes (WRs 1-5) were much higher (50-100 fold) than for 
micelle/pDNA complexes (WRs 15-30) (Fig. 2.10. This indicates that the surface shielding 
conferred by the addition of bPEI1.8kDa may prevent bioactivity loss of pDNA via 
protection from nuclease-mediated degradation. Nevertheless, “fresh” 
micelle/pDNA/bPEI1.8kDa complexes (WRs 1-5) still had 20-40-fold lower transgene 
expression levels than “fresh” bPEI25kDa/pDNA (N/P 5) complexes (Fig. 2.13). 
Interestingly however, “reconstituted” micelle/pDNA/bPEI1.8kDa complexes (WRs 
1-5) had enhanced transfection efficiencies up to 16 times higher than the transfection 
values of their “fresh” micelle/pDNA/bPEI1.8kDa complex counterparts (WRs 1-5) (Fig. 
2.13). This was especially true for micelle/pDNA/bPEI1.8kDa complexes that were less 
than 200 nm in diameter (i.e., WRs 1, 2, and 5), where the process of lyophilization and 
reconstitution significantly enhanced their transfection efficiencies compared to their 
“fresh” polyplex counterparts (p<0.001). The transfection efficiency of “reconstituted” 
micelle/pDNA/bPEI1.8kDa complexes (WR 1) was much closer (3.6 times lower) to 





















































micelle/pDNA/bPEI1.8kDa complexes (WR 1; 59-fold lower) (Fig. 2.13). Rather interestingly 
“reconstituted” micelle/pDNA/bPEI1.8kDa complexes (WR 1) had approximately 39-fold  
higher transfection efficiency than “reconstituted” bPEI25kDa/pDNA (N/P 5) complexes 
prepared from sticky and lyophilized bPEI25kDa/pDNA (N/P 5). Given the effect of  
reconstitution on bPEI25kDa/pDNA complexes, the benefit of transfection enhancement 
for “reconstituted” micelle/pDNA/bPEI1.8kDa complexes (WR 1) may increase its appeal 
as a potential alternative to bPEI25kDa as a transfection reagent because the micelle 
system was also considerably less cytotoxic than bPEI25kDa.  
Although the micelle possesses more biocompatibility than bPEI25kDa, polyplex 
cytotoxicity can also significantly affect transfection results. Thus, the cytotoxicity of 
“fresh” and “reconstituted” polyplexes (WRs 1-5) was evaluated in MCF7 cells and 
compared to the cytotoxicity of “fresh” bPEI25kDa/pDNA complexes (N/P 5). As shown in 
Fig. 2.14, the cell viability of “fresh” micelle/pDNA complexes was over 90% compared 
to the untransfected control cells and was not statistically different from “reconstituted” 
micelle/pDNA complexes. Although bPEI1.8kDa was introduced into the micelle/pDNA 
complexes, the polyplexes still showed cell viability of approximately 90% regardless of 
whether they were subjected to lyophilization and reconstitution. Overall, the 
cytotoxicity of micelle-based polyplexes was significantly lower than “fresh” 
bPEI25kDa/pDNA complexes (>90% versus <75%, p<0.01).  
To investigate why “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) complexes 
showed higher transfection efficiency than “fresh” micelle/pDNA/bPEI1.8kDa (WR 1) 
complexes but lower transfection efficiency than “fresh” bPEI25kDa/pDNA (N/P 5) 
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complexes, cellular uptake of complexed pDNA was analyzed in MCF7 cells. The number 
of DNA molecules per cell was quantified using flow cytometry. As shown in Fig. 2.15, 
from among the different polyplexes tested, “fresh” bPEI25kDa/pDNA (N/P 5) showed the 
highest cellular uptake. “Reconstituted” micelle/pDNA/bPEI1.8kDa complexes had higher 
up-take compared to their “fresh” counterparts. These differences in the amount of 
intracellular pDNA support the benefit of reconstitution on increasing the transfection 
efficiency of micelle/pDNA/bPEI1.8kDa (WR 1).  
2.4.5. Scalability of (PLGA36kDa)2-b-bPEI25kDa  
Micelle/pDNA/bPEI1.8kDa Complexes 
While the transfection results using “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 
1) complexes appear very promising in vitro, in vivo and clinical applications of 
polymeric gene vectors would require large scale polyplex preparation with limited 
polyplex volume. In addition, one concern in gene therapy is whether transfection and 
cytotoxicity results obtained using small scale polyplex doses can be scaled up 
proportionately and translated to reflect the transfection and cytotoxicity associated 
with large scale polyplex doses. Thus, pDNA dose-dependent transfection and 
cytotoxicity studies of “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) complexes were 
conducted in MCF7 cells to evaluate the effects of increasing pDNA doses. 
MCF7 cells were transfected with “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) 
complexes at varying final concentrations of pDNA ranging from 0.5-10 µg/mL (1-20 µg 
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levels increased linearly with increasing pDNA dose; after accounting for cell viability, 
transfection increased nearly 50-fold with a pDNA dose of 20 µg (10 µg/mL) versus 1 µg 
(0.5 µg/mL). The cytotoxicity of micelle/pDNA/bPEI1.8kDa complexes was fairly low, with 
cell viabilities of 80% or higher at every pDNA concentration tested (Fig. 2.16(b)). Thus, 
this (PLGA36kDa)2-b-bPEI25kDa polymeric micelle-based system could be used to deliver 
larger quantities of pDNA without causing undue toxicity.  
Based on our initial findings, this micelle/pDNA/bPEI1.8kDa polyplex system has 
many favorable characteristics that make it an attractive gene delivery system. In 
addition, the structure of the particular copolymer used allows the possibility to bestow 
additional functionalities and further optimize the carrier. For instance, cationic 
polyplexes tend to have decreased colloidal stability due to nonspecific interactions with 
serum proteins and nontarget cells. This shortcoming could be overcome by conjugating 
poly(ethylene glycol) (PEG) which would reduce protein interactions and increase 
polyplex stability. Another option is to modify the carrier by conjugating targeting 
moieties to the polymeric micelle-surface which would enhance cellular internalization 
in the cell population of interest. Finally, because of the core-shell structure of our 
micelle system, there is the potential to utilize the core by loading it with hydrophobic 
therapeutic agents such as doxorubicin, dexamethasone or taxol among others, thus 
creating a dual-agent delivery system that can be lyophilized for storage and easily 




















The goal of this study was to create a charged polymeric micelle-based system 
for gene therapeutics delivery that maintained efficacy following lyophilization and 
reconstitution. Using our (PLGA36kDa)2-b-bPEI25kDa block copolymer, we were able to 
create a micelle system that remained stable following reconstitution. After 
complexation with pDNA, the micelle/pDNA system retained its particle size and zeta 
potential characteristics following lyophilization and reconstitution. Finally, the 
reconstituted system was able to successfully transfect breast cancer cells using a 
reporter gene with minimal toxicity to the cells. Although extrapolating the use of 
nonviral systems to treat human disease is still somewhat premature, we are 
encouraged by evidence from our lab showing the potential of this particular system as 
a reconstitutable charged polymeric micelle gene delivery system. 
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DEXAMETHASONE-LOADED CHARGED PLGA-b-PEI MICELLES 
 





 This study investigated the potential of dexamethasone to enhance the nuclear 
accumulation and subsequent gene expression of DNA delivered using a charged 
polymeric micelle-based gene delivery system. Three different copolymers having a 
PLGA-b-bPEI25kDa block co-polymer structure were synthesized and used to prepare 
cationic polymeric micelles loaded with dexamethasone; PLGA36kDa-b-bPEI25kDa 
(PLGA:bPEI block ratio = 1), (PLGA36kDa)2-b-bPEI25kDa (PLGA:bPEI block ratio = 2), and 
(PLGA48kDa)2-b-bPEI25kDa (PLGA:bPEI block ratio = 2). All three polymer systems retained 
proton-buffering ability of the bPEI25kDa block within the endosomal pH range. Particle 
size and zeta potential characteristics of dex-loaded micelles and dex-loaded 
micelle/pDNA/bPEI1.8kDa complexes were retained following reconstitution, so 
reconstituted complexes were prepared and used for all subsequent studies. 
Transfection levels using dex-micelle/pDNA/bPEI1.8kDa complexes were generally higher 
than their counterpart blank micelle/pDNA/ bPEI1.8kDa complexes, with the most 
dramatic increases in transfection levels using complexes with WR < 1. The dex-
micelle/pDNA/bPEI1.8kDa systems showed very low cytotoxicity in MCF7 cells with cell 
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viabilities of 90% or higher for all conditions tested. These results suggest that this 
dexamethasone-loaded polymeric micelle-based system could be used to decrease the 
amount of polymer required for transfection, and as well as increase nuclear 
accumulation of the vehicle for gene and drug delivery applications.  
3.2. Introduction 
 
Gene therapy is a potential therapeutic strategy to treat diseases caused by 
missing or mutated genes. This can be accomplished by supplementing gene expression, 
replacing a mutated gene with a normal copy, or altering gene expression to correct 
phenotypes caused by defective genes [1-3]. The discovery that a genetic disease 
phenotype could be corrected by introducing exogenous DNA into a cell established the 
concept of human gene therapy [4-6] and since then numerous studies have been 
conducted in the quest to translate this knowledge into clinically relevant gene therapy 
applications. Some success has been achieved using viral-based delivery systems and 
lipid-based delivery systems and several clinical trials have been conducted using gene 
therapy to treat a variety of maladies [7-10]. Although viral-based systems have been 
able to attain high cell infection and gene expression rates, numerous concerns 
regarding their safety and immunogenicity have tainted their widespread development 
for clinical use and increased interest in developing nonviral delivery vectors [11-16].  
Nonviral delivery systems are typically classified as lipid-based or polymer-based 
systems. Polymer-based systems in particular have many desirable features including 
excellent biocompatibility, no tumorigenicity and low immunogenicity. More 
importantly, polymer-based systems can easily be customized and adapted to suit a 
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particular system [12]. Polymers can be designed to include traits such as endosomal 
disruption [17, 18], decreased toxicity [19-21], and targeted-delivery to specific cell 
types [22, 23] or even the nucleus [24, 25]. Numerous polymer combinations have been 
designed and investigated as delivery systems. Block copolymer micelle systems 
specifically have been shown to modulate drug pharmacokinetics and prolong systemic 
circulation [26], making them a strong candidate for drug delivery applications.  It has 
been shown that copolymers with a hydrophobic block-charged hydrophilic block 
composition such as poly(ε-caprolactone)-bPEI1.8kDa [27] or poly(lactide-co-glycolide)-b-
bPEI25kDa [28] can naturally self-assemble into core-shell micelles, creating different 
compartments that can be loaded with hydrophobic drugs (core) and gene drugs (shell).  
Despite the relative safety and immunogenicity of these carriers, polymer-based 
systems are plagued by low cell transfection and gene expression rates compared to 
levels attained using viral carriers. Numerous combinations of existing and novel 
polymer systems have been investigated to increase cell transfection using mechanisms 
such as engineering endosomal escape mechanisms, increasing cellular uptake through 
prolonged systemic circulation and targeting, and by enhancing nuclear penetration [29-
32]. Increasing nuclear delivery is particularly important, as the gene has an increased 
chance of transfection and subsequent expression if it can enter the nucleus, which 
oftentimes is a limiting factor for successful transfection.  
Transport into and out of the cell nucleus is highly regulated, and occurs through 
channels decorating the nuclear membrane called nuclear pore complexes [33]. Small 
molecules (diameter < 35nm, MW < 40kDa) such as water, glucose, and oxygen can 
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easily diffuse in and out of the channel, but larger molecules (diameter > 35nm, MW > 
40kDa) require a nuclear localization signal and the aid of soluble nuclear transport 
factors in order to enter the nucleus [34]. Molecules that do not meet either of these 
two criteria are excluded from the nuclear compartment [35, 36]. While viruses have 
evolved specific mechanisms to overcome these natural cellular defenses and achieve 
nuclear delivery of their DNA with high efficiency, such abilities are sorely lacking in 
current polymeric-gene delivery candidates [37]. Methods to increase the nuclear 
delivery of therapeutic genes could augment gene transfection rates and enhance 
overall gene expression levels. This includes creating smaller polyplex particles that can 
easily diffuse through the nuclear pores, or conjugating nuclear localization signals or 
nuclear proteins to the carrier surface which would increase nuclear localization of the 
particles. Another option is to utilize receptor-mediated nuclear transport by identifying 
a receptor such as the glucocorticoid receptor and incorporating the corresponding 
ligands into the polyplex, thereby increasing nuclear accumulation and enhancing 
overall gene expression. One ligand of the glucocorticoid receptor in particular, 
dexamethasone, has been shown to have a dilatory effect on nuclear pores. 
Dexamethasone is a hydrophobic steroid hormone that upon binding to the 
glucocorticoid receptor causes translocation from the cytosol into the nucleus. It has 
been shown that cells treated with dexamethasone displayed transient dilation of the 
nuclear pore complexes which caused them to expand up to 135nm in diameter [34]. 
Others have demonstrated that the presence of dexamethasone facilitated the 
transport of polymer/DNA complexes into the nucleus, and conjugating dexamethasone 
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to the polymer increased transfection efficiency [38, 39]. Rebuffat et al. conjugated 
dexamethasone to DNA directly and evaluated gene transfer. They demonstrated that 
the dexamethasone-DNA conjugate clearly enhanced gene transfer, and this result was 
directly correlated to the presence of dexamethasone [40, 41]. As the nuclear entry of 
polymer/DNA complexes is currently hindered due to its larger diameter and lack of 
nuclear localization signals, dexamethasone could potentially be used to increase 
nuclear localization of polyplexes and subsequently enhance gene transfection 
efficiency and expression.  
This study was designed to investigate the potential of using a charged polymeric 
micelle-based gene delivery system that showed enhanced nuclear delivery and 
increased gene expression. We had previously reported the creation of a micelle system 
based on a copolymer of branched polyethylenimine (bPEI) and poly(lactide-co-
glycolide) (PLGA) ((PLGA36kDa)2-b-bPEI25kDa). The resulting copolymer self-assembled into 
a core-shell micelle structure and formed complexes with pDNA which could be 
lyophilized and reconstituted, and in fact achieved higher transfection efficiencies 
following reconstitution [28]. This copolymer along with two other bPEI-PLGA based 
polymers synthesized for this application (PLGA36kDa-b-bPEI25kDa and (PLGA48kDa)2-b-
bPEI25kDa) were used to form micelles that were co-loaded with the hydrophobic drug 
dexamethasone within the core and a gene drug in the shell to form our delivery 
system. The resulting dexamethasone-loaded micelle/pDNA complexes were evaluated 
for particle size, zeta potential, dexamethasone-loaded content, pDNA condensation 
ability, nuclear localization, and cell transfection efficiency.  
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 Poly(lactide-co-glycolide) (PLGA; Resomer®503H; lactide:glycolide=1:1 
(mole/mole); approximate MW 36kDa) with a carboxylic group at one end and 
poly(lactide-co-glycolide) (PLGA; Resomer®504H; lactide:glycolide=1:1 (mole/mole); 
approximate MW 48kDa) with a carboxylic group at one end were purchased from 
Boehringer Ingelheim Pharm GmbH & Co. KG (Germany). Two branched 
polyethyleneimines having Mr 1.8kDa (bPEI1.8kDa) and Mw 25kDa (bPEI25kDa; Mn 10kDa) 
were purchased from Polysciences, Inc. (Warrington, PA) and Sigma-Aldrich Co. (St. 
Louis, MO) respectively. Fetal bovine serum (FBS), penicillin/streptomycin, and 0.25% 
trypsin/EDTA were purchased from Gibco BRL (Grand Island, NY). Triethylamine (TEA), 
N,N’-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), RPMI1640 cell 
culture medium powder, sodium bicarbonate, D-glucose, 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid sodium salt (HEPES), human recombinant insulin, Ca2+-free and 
Mg2+-free Dulbecco’s phosphate buffered saline (DPBS), 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), dexamethasone, 
and agarose were purchased from Sigma-Aldrich Co. (St. Louis, MO). Luciferase assay kit 
was obtained from Promega Co. (Madison, WI). Spectrapor dialysis membrane MWCO 
15kDa was purchased from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). 
Ethidium bromide (EtBr) and the Biocinchoninic Acid Protein Assay Kit (BCA) were 
obtained from Thermo Fisher Scientific, Inc. (Waltham, MA). Plasmid DNA (pDNA) 
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encoded with the firefly luciferase reporter gene (gWiz-Luc) was purchased from 
Aldevron, Inc. (Fargo, ND).  
3.3.2. Cell Culture 
In this study, MCF7 cells (a human breast adenocarcinoma cell line) were used 
for determining the cytotoxicity of micelles and polyplexes, polyplex transfection and 
nuclear localization of polyplexes. All experiments used MCF7 cells cultured in 
RPMI1640 cell culture medium supplemented with insulin (4 mg/L), glucose (2 g/L), 10% 
heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin antibiotics at 
37°C in humidified air containing 5% CO2. 
3.3.3. Synthesis and Characterization of Amphiphilic Copolymers 
 Several block copolymers composed of PLGA and bPEI25kDa ((PLGA)n-b-bPEI25kDa) 
were synthesized by conventional condensation between the carboxylic acid group from 
PLGA and the amine groups from bPEI25kDa following previously published methods [28]. 
In brief, PLGA (50µmol or 100µmol) and bPEI25kDa (50µmol) were dissolved separately in 
DMSO (100mL) and stirred independently for 4 hours. Then the two polymer solutions 
were mixed together along with DCC (1mmol), NHS (1mmol), and TEA (0.1mL) and 
polymerization was carried out at room temperature (RT) for 48 hours under constant 
stirring. About 100mL of deionized (DI) water was added to the reaction mixture and 
stirred for 2 hours; then the polymer solution was transferred to a dialysis tube (MWCO 
15kDa) and dialyzed against DI water for 2 days to remove any unreacted bPEI25kDa. 
Unreacted PLGA was removed by filtration at a later stage following micelle formation. 
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The dialysis solution was lyophilized to obtain the resulting block copolymers. The 
chemical structures were confirmed by 1H-NMR spectroscopy.  
3.3.4. Preparation and Characterization of Dexamethasone-Loaded Micelles 
Micelles were prepared using standard dialysis techniques. For each (PLGA)n-b-
bPEI25kDa copolymer, the polymer was dissolved in DMSO at a concentration of 10mg/mL 
and stirred for 4 hours at RT. Dexamethasone was added to the polymer solution at a 
1:1 weight ratio of polymer to drug, and the solution was stirred for an additional 2 
hours. A volume of HEPES buffer (20mM, pH 7.4) equivalent to DMSO was added to the 
reaction mixture which was stirred for an additional 2 hours. The reaction mixture was 
transferred to a dialysis membrane (MWCO 15kDa) and dialyzed against HEPES 20mM 
pH 7.4 buffer at 4°C for 24 hours followed by dialysis against deionized water for an 
additional 6 hours to remove any residual salt. The resulting micelle solution was 
filtered using a 0.22µm filter to remove any unreacted PLGA remaining from the 
synthesis (which precipitates in water) and free dexamethasone (which also precipitates 
in water) and the remaining solution was lyophilized and stored protected from light at  
-20°C until needed.  
Particle size and zeta potential of freshly-prepared and reconstituted 
dexamethasone-loaded micelles were measured in HEPES 20mM pH 7.4 buffer at room 
temperature using a Zetasizer 3000HSA (Malvern Instruments Inc., Worcestershire, UK) 
with a fixed wavelength of 677nm and a constant angle of 90°.  
Micelles were titrated using traditional acid-base titration methods to evaluate 
the amount of proton buffering capacity retained from the bPEI25kDa block in the various 
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(PLGA)n-b-bPEI25kDa micelles [18, 21]. Each of the (PLGA)n-b-bPEI25kDa micelles were 
separately dispersed in 3mL of 150mM NaCl and titrated from pH 7.4 to pH 3 using 0.1N 
HCl. The proton buffering ability of the (PLGA)n-b-bPEI25kDa micelles was compared to 
bPEI25kDa alone within the pH range 7.4-5.1 because this pH range correlates with typical 
endolysosomal pHs. Buffering capacity (%) was calculated using the following equation 
[42]: 
 
where ∆VHCl is the volume of the HCl solution (0.1N) that decreased the pH value of the 
polymer solution from pH 7.4 to pH 5.1, CHCl is the concentration of the HCl solution 
(0.1N), and N is the total moles of protonable amine groups contained in the polymer.  
 The amount of dexamethasone loaded into the micelles was determined using 
UV spectroscopy. Prior to lyophilization, freshly prepared micelles were collected in pre-
weighted falcon tubes. The volume of the bulk was measured, and a 200µL sample from 
each of the freshly prepared (PLGA)n-b-bPEI25kDa micelles was removed from the bulk 
and lyophilized separately. Following lyophilization, the final weight of the dried bulk 
micelles was measured and the mass of the dex-loaded micelles was determined. The 
separate 200µL sample was dissolved in 1mL of DMSO and stirred for 6 hours to ensure 
complete dissolution of the micelles. The absorbance of the micelle samples was 
measured using UV spectroscopy at 250nm wavelength. To create a standard curve, 
dexamethasone alone was dissolved in DMSO at several concentrations, stirred for 6 
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hours to ensure complete dissolution, and the absorbance of the samples was measured 
at 250nm.  The amount of dexamethasone contained in the micelles was calculated 
based on the standard curve.  
Cytotoxicity of dexamethasone-loaded (PLGA)n-b-bPEI25kDa micelles was assessed 
using standard protocols for MTT-based cell viability assay [18, 21]. MCF7 breast cancer 
cells were seeded in 96-well plates at a density of 5000 cells/well in culture medium 
(0.1mL). Varying concentrations of sample solutions (10µL) were added to each well and 
incubated for 24 hours at 37°C in a cell culture incubator. Then MTT solution (10 µL, 
5mg/mL) was added to each well and the plates were returned to the incubator for an 
additional 4 hours. Media was completely removed, 100µL of DMSO was added to each 
well, and the plates were incubated for 10 minutes at 37°C to allow the formazan 
metabolites to dissolve. Absorbance was measured at 570nm using a microplate reader 
(SpectraMax® M2, Molecular Devices, Sunnyvale, CA) and used to calculate cell viability.  
3.3.5. Preparation and Characterization of Dexamethasone-Loaded 
Micelle/pDNA/bPEI1.8kDa Complexes 
Micelle solutions were mixed with pDNA in HEPES buffer (20 mM, pH 7.4) 
containing 5% glucose (HBG) and incubated at RT for 30 minutes. Following 
complexation the polyplexes were mixed with a small amount of bPEI1.8kDa at a weight 
ratio of 2.5µg bPEI1.8kDa per 1µg pDNA. This method was used to create polyplexes for 
particle size and zeta potential measurements, gel retardation studies, gene transfection 
and cell viability tests.  
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Complexation between dexamethasone-loaded micelles and pDNA was 
evaluated by gel retardation and dye quenching methods [18, 23]. For the gel 
retardation studies, polyplex solution (0.5μg pDNA in 10μL) was loaded onto a 0.8% 
agarose gel containing EtBr (100ng/mL). Electrophoresis was run using 0.5X Tris-buffer 
containing boric acid and EDTA (TBE) at 100V for 60 minutes. The gel was imaged using 
an Alpha Innotech FluorChem FC2® instrument with Alpha View Software (Cell 
Biosciences, Santa Clara CA).  
For the dye quenching assays, pDNA was mixed with ethidium bromide (EtBr) at 
a mole ratio of five nucleotides per one EtBr and pre-incubated in the dark for 30 
minutes at RT. Using EtBr-intercalated pDNA, polyplexes were prepared following the 
same method described above. Polyplexes were excited at 515 nm and the emitted 
fluorescence was measured at 595 nm using a Spectramax® M2 spectraphotometer 
(Molecular Devices, Sunnyvale CA).  
Particle size and zeta potential of polyplexes prepared using reconstituted 
dexamethasone-loaded micelles were measured at RT using a Zetasizer 3000HSA 
(Malvern Instruments Inc., Worcestershire, UK) with a fixed wavelength of 677 nm and a 
constant angle of 90°.  
In vitro transfection using reconstituted polyplexes was evaluated using MCF7 
cells as previously reported [28, 43]. Transfection was evaluated using each of the three 
dex-loaded micelle systems separately to form complexes. A separate transfection 
experiment was also conducted using blank (PLGA36kDa)2-b-bPEI25kDa micelles and cells 
were co-treated simultaneously with the blank micelle/pDNA/bPEI1.8kDa complexes and 
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free dexamethasone (0nM to 10µM) to confirm the effect of dexamethasone on gene 
transfection. Cells were seeded in 6-well plates at a density of 5 × 105 cells/well and 
cultured for 24 hours in 2mL culture medium. One hour prior to transfection, the cell 
culture medium was removed and replaced with serum-free insulin-free culture medium 
(2 mL). Polyplexes were added to the wells (20 µL volume, pDNA content was fixed at 1 
µg/well) and cells were incubated at 37°C for 4 hours. After the 4-hour transfection 
period, the serum-free medium was replaced with complete culture medium 
(supplemented with serum and insulin) and incubated for another 44 hours. Following 
incubation, culture medium was removed and cells were rinsed once with DPBS and 
lysed using a reporter lysis buffer. Luciferase gene expression (relative luminescence 
units (RLU)) was quantified by following the manufacturer’s protocol for the luciferase 
assay. Protein content in the cells was evaluated by the BCATM protein assay. Gene 
transfection efficiency is reported as RLU/mg protein.  
In vitro cytotoxicity of reconstituted polyplexes was determined by MTT-based 
cell viability assay. The experimental procedure was the same as previously described 
for in vitro transfection except the cell number used (2.5×105 cells/well; 12-well plates) 
and the polyplex dose (10 µL; 0.5 µg pDNA/well). After completing the 48-hour 
transfection procedure, MTT solution (0.1 mL; 5 mg/mL) was added to the cells (in 1 mL 
of culture medium). After an additional 4-hour incubation, the MTT-containing medium 
was removed. The resulting formazan crystals produced by living cells were dissolved in 
1mL of DMSO and absorbance was measured at 570 nm using a microplate reader [28].  
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The statistical significance of the data was evaluated by conducting unpaired 
Student’s t-test with a confidence level of p<0.05, one-variable Analysis of Variance 
(ANOVA) and two-variable Analysis of Variance (ANOVA).  
3.4. Results and Discussion 
3.4.1. Synthesis and Characterization of (PLGA)n-b-bPEI25kDa  
Amphiphilic Copolymers 
 Amphiphilic cationic block copolymers composed of bPEI25kDa and either 
PLGA36kDa or PLGA48kDa were synthesized through a conjugation reaction between the 
primary amines of bPEI25kDa and the monocarboxylated PLGAs (Fig. 3.1). Synthesis and 
block ratio of the copolymers (PLGA to bPEI25kDa) were confirmed by 
1H-NMR. Following 
previously reported methods [28], the PLGA blocks were completely degraded into their 
lactic acid and glycolic acid subunits using 1M NaOH in D2O in order to get an accurate 
reading of the block ratio between PLGA and bPEI25kDa. Degradation products were 
completely soluble in the aqueous solution and based on the integration ratio of either 
lactic acid (or glycolic acid) and bPEI25kDa, the block ratio of PLGA to bPEI25kDa was 
calculated to be 0.85 for PLGA36kDa-b-bPEI25kDa copolymer, 1.93 for (PLGA36kDa)2-b-
bPEI25kDa copolymer, and 2.38 for (PLGA48kDa)2-b-bPEI25kDa copolymer (Table 3.1).   
3.4.2. Preparation and Characteristics of Dexamethasone-Loaded  
(PLGA)n-b-bPEI25kDa Micelles 
 The amphiphilic nature of the block copolymers was used to form positively-
charged dexamethasone-loaded micelles using conventional dialysis methods. The  
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Figure 3.1: Reaction schematic for (PLGA)n·b·bPEI2SkDiI copolymer 
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Table 3.1: Summary of (PLGA),,-b-bPE I Block Copolymer Characteristics 
PLGA36kDa-b-
1 0.85 40 .6 kDa 24.6% Diblock bPE I25kDa 
( PLGA36kDa)2-b-
2 1.93 79.5 kDa 12 .6% Triblock bPE I25kDa 
( PLGA48kDa)2-b- 2 2.38 124.2 kDa 8.1% Triblock bPE I25kDa 
125 
 
micelles assembled into a core-shell structure where dexamethasone was contained 
within the hydrophobic PLGA core and bPEI25kDa formed the hydrophilic shell (or 
corona). The average particle size diameter was 70-80 nm for cationic dexamethasone- 
loaded micelles made from PLGA36kDa-b-bPEI25kDa, 70 nm for cationic dexamethasone-
loaded micelles made from (PLGA36kDa)2-b-bPEI25kDa, and 80-100 nm for cationic 
dexamethasone-loaded micelles made from (PLGA48kDa)2-b-bPEI25kDa (Zavg-particle size 
relevant to hydrodynamic size) (Fig. 3.2). Correspondingly, the average zeta potential 
was 35-40 mV for dexamethasone-loaded micelles made from PLGA36kDa-b-bPEI25kDa, 35-
45 mV for cationic dexamethasone-loaded micelles made from (PLGA36kDa)2-b-bPEI25kDa, 
and 30-40 mV for cationic dexamethasone-loaded micelles made from (PLGA48kDa)2-b-
bPEI25kDa (Fig. 3.2). Particle size and zeta potential characteristics of micelles in aqueous 
solution were retained following reconstitution because the strong positively-charged 
corona prevented the formation of aggregated micelles due to charge repulsion. The 
relatively high molecular weight of PLGA used (MW 36kDa or 48kDa) endowed the 
micelle core with strong hydrophobicity [44-46] and slow degradation rate [44, 47, 48]. 
However, due to the presence of dexamethasone in the micelle core, storage of the 
dexamethasone-loaded micelles in aqueous solution would not be prudent because 
long-term exposure to changes in temperature, humidity, light, etc. could alter the 
physicochemical characteristics of the formulation and more importantly affect the 
biological function of the dexamethasone. We had previously found that (PLGA36kDa)2-b-
bPEI25kDa micelles retained their physicochemical properties following lyophilization and 
reconstitution [28]. To determine whether this property extended to the   
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Figure 3.2: Particle size and zeta potential of dexamethasone-loaded (PlGA)n-b-bPElmDa 
micelles before and after reconstitution. (n=4; mean ± SD) 
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dexamethasone-loaded micelle systems, particle size and zeta potential of all 
dexamethasone-loaded micelle formulations were monitored before and after 
lyophilization. As shown in Fig. 3.2, particle size and zeta potential for the reconstituted 
micelle systems were similar to those of the fresh micelle systems. 
 The proton-buffering capacity of bPEI25kDa has been well established. In order to 
determine how much proton-buffering ability was retained in each of the (PLGA)n-b-
bPEI25kDa dex-loaded micelles, micelles were dissolved individually in 3mL of 150mM 
NaCl at 0.5 mg/mL ((PLGA48kDa)2-b-bPEI25kDa = 3.28µmol in 3mL; (PLGA36kDa)2-b-bPEI25kDa = 
4.49µmol in 3mL; PLGA36kDa-b-bPEI25kDa = 7.57µmol in 3mL)and titrated from pH 7.4 to 
pH 3.0 by adding 0.1N HCl. Because the weight percentage of bPEI25kDa (based on Mn) in 
the copolymers varied ((PLGA48kDa)2-b-bPEI25kDa) = 9.7%, (PLGA36kDa)2-b-bPEI25kDa = 12.6%,  
PLGA36kDa-b-bPEI25kDa = 22.3%), the buffering capacity was compared to bPEI25kDa at 0.5 
mg/mL (3.49µmol in 3mL) and 0.75 mg/mL (5.23µmol amines in 3mL). As shown in 
Figure 3.3, all three dex-loaded micelle systems retained proton-buffering ability within 
the endosomal pH range (pH 5.1-7.4) although overall buffering capacity decreased 
following conjugation ((PLGA48kDa)2-b-bPEI25kDa) = 5.5%, (PLGA36kDa)2-b-bPEI25kDa = 10.6%,   
PLGA36kDa-b-bPEI25kDa = 12.3%) compared to free bPEI25kDa alone (average 17.2% from the 
two different concentrations). The buffering capacity of the bPEI25kDa block was affected 
by both the block ratio of PLGA:bPEI (1:1 or 2:1) and the molecular weight of the PLGA 
block (MW 36kDa or 48kDa) due to the decreased ability of protons to access and 














strong hydrophobic PLGA block(s), which reduced the overall buffering ability of the 
copolymer [28]. 
The amount of dexamethasone incorporated into each of the micelle systems 
was determined by measuring the absorbance of dexamethasone at 250nm wavelength 
using standard UV spectroscopy. Dexamethasone content was determined to be  
17.4wt% in dex-loaded PLGA36kDa-b-bPEI25kDa micelles, 7.6wt% in (PLGA36kDa)2-b-bPEI25kDa 
micelles, and 9.2wt% in (PLGA48kDa)2-b-bPEI25kDa) micelles.  
 The toxicity of the dexamethasone-loaded polymeric micelles was compared to 
the toxicity of free dexamethasone and control polymers (bPEI25kDa and bPEI1.8kDa). As 
expected, the dexamethasone-loaded polymeric micelles had quite low toxicity 
compared to bPEI25kDa alone (Fig. 3.4). The IC50 for all the polymers was greater than 
200µg/mL, much higher than for bPEI25kDa alone (~12 µg/mL). The cytotoxicity 
contribution from the presence of dexamethasone in the core (100nM or less) and the 
concentration of the small amount of bPEI1.8kDa used in transfection studies (2.5 µg per 1 
µg pDNA) was negligible; cell viabilities were unaffected by the presence of 
dexamethasone and higher than 90% for the concentration of bPEI1.8kDa used.  
3.4.3. Preparation and Characteristics of Dexamethasone-loaded  
(PLGA)n-b-bPEI25kDa Micelle/pDNA/bPEI1.8kDa Complexes 
 Reconstituted dexamethasone-loaded (PLGA)n-b-bPEI25kDa micelles were mixed 
with pDNA to form complexes and then coated with a small amount of bPEI1.8kDa to 
ensure that the pDNA was completely shielded (abbreviated as dex-
micelle/pDNA/bPEI1.8kDa complexes). It had been previously determined that adding a  
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small amount of bPEI1.8kDa (2.5µg per 1µg pDNA) completely shielded any exposed pDNA 
on the surface of micelle/pDNA complexes made using blank (PLGA36kDa)2-b-bPEI25kDa 
micelles [28]. Since there were some differences in the composition of the three micelle 
systems it was confirmed that this amount of bPEI1.8kDa was sufficient to shield the pDNA 
in all dexamethasone-loaded (PLGA)n-b-bPEI25kDa micelle/pDNA complexes (Fig. 3.5). 
Having determined that the dexamethasone-loaded micelles retained their particle size 
and zeta potential characteristics following reconstitution, the next step was to confirm 
that dexamethasone-loaded micelle/pDNA/bPEI1.8kDa complexes remained complexed to 
the pDNA following reconstitution. Particle size, zeta potential and complexation of the 
polyplexes were monitored after reconstitution. As shown in Figure 3.6, pDNA remained 
shielded prior to (Figure 3.6a) and following lyophilization and reconstitution (Figure 
3.6b), confirming that the reconstitution process did not negatively impact the 
physicochemical properties of polyplexes (Figure 3.6 a & b). In fact pDNA shielding 
increased following reconstitution as demonstrated by the decrease in fluorescence 
detected in the EtBr quenching assay (Fig. 3.7). Following this finding, only reconstituted 
complexes were used for all subsequent evaluation. Particle sizes of the reconstituted 
polyplexes were similar regardless of copolymer composition or weight ratio (100-
180nm) and zeta potential remained strongly positive (30-40mV) (Figure 3.8). Previously 
we had shown that the particle size had increased considerably for blank (PLGA36kDa)2-b-
bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes at weight ratios 3 and 4 due to the 
formation of large aggregates [28], whereas in this study none of the dex-
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ratios (3 and 4). This is probably due to the difference in zeta potential between the two 
micelle groups. The blank micelles had a zeta potential of 15-25mV, whereas the dex- 
loaded micelles had zeta potentials of 30-45mV. This stronger positive value most likely 
prevented the formation of large aggregates during complexation due to stronger 
charge repulsion between the micelles. 
3.4.4. Biological Characteristics of Dexamethasone-Loaded  
(PLGA)n-b-bPEI25kDa Micelle/pDNA/bPEI1.8kDa Complexes 
 Transfection experiments were performed in MCF7 breast cancer cells using 
reconstituted dex-loaded micelle/pDNA/bPEI1.8kDa complexes and compared to 
reconstituted blank micelle/pDNA/bPEI1.8kDa complexes and fresh or reconstituted 
bPEI25kDa/pDNA (N/P 5) complexes (Figure 3.9 (a-i)). Transfection efficiencies achieved 
using the dex-loaded micelle/pDNA/bPEI1.8kDa systems were slightly lower than fresh 
bPEI25kDa/pDNA (N/P 5) complexes, although expression levels were fairly close for all 
weight ratios tested, ranging from only 1.4-fold to 4.8-fold lower expression, even for 
polyplexes with weight ratio (WR) < 1 (Figure 3.9(a), 3.9(d), 3.9(g)). Interestingly, one 
complex condition surpassed bPEI25kDa/pDNA (N/P 5) transfection levels; PLGA36kDa-b-
bPEI25kDa micelle/pDNA/bPEI1.8kDa WR 3 complexes achieved 3.3-fold higher expression 
compared to bPEI25kDa/pDNA (N/P 5) control complexes (Figure 3.9(a)). Since there was 
only one PLGA block in this particular co-polymer (diblock structure), the bPEI25kDa block 
was less affected by the conjugation and was more effective in aiding endosomal escape 
and gene transfection compared to the other two triblock copolymers which had two 
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Figure 3.9: Transfection efficiencies of reconstituted dex-micelle!pDNA!bPEI1.8kOa complexes 
(a) Transfection efficiency of reconstituted PlGA36kOa -b-bPEI2SkOa dex-micelle!pDNA!bPEI1.8kDa complexes (1 
~g of pDNA) in MCF7 cells (5xlO' cells at seed ing), (b) reconstituted PlGA'Gko. -b-bPEI 2SkO• blank 
micelle/pDNA/bPEI1.8ko.complexes (1 ~g of pDNA) in MCF7 cells (5xlO' cells at seeding), 
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Figure 3,9 continued: (d) Transfection efficiency of reconstituted (PLGA36kO.l,-b-bPEI2SkO. dex-
micelle/pDNA/bPEI1.8ko, complexes (1 ~g of pDNA) in MCF7 cells (5xlO' cells at seeding), (e) reconstituted 
(PLGA,Gko.l,-b-bPEI2SkO• blank micelle/pDNA/bPEI1.8ko.complexes (1 ~g of pDNA) in MCF7 cells (5xlO' cells 
at seed ing), (f) fresh and reconstituted bPEI2SkO. /pDNA (NIP 5) complexes, (n=4; mean ± SD) 
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Figure 3.9 continu ed: (g) Transfection effici ency of reconstituted (PlGA48kD .. h-b-bPEI2SkDiI dex-
micelle/pDNA/bPEll.8ko, complexes (1 ~g of pDNA) in MCF7 cells (5xlO' cells at seeding), (h) reconstituted 
(PlGA48kO. ),-b-bPEI2SkO. blank micelle/pDNA/bPEI 1.8ko. complexes (1 ~g of pDNA) in MCF7 cells (5xlO' cells 
at seed ing), (i) fresh and reconstituted bPEI2Sko.lPDNA (NIP 5) complexes. (n=4; mean ± SD) 
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blank micelle/pDNA/bPEI1.8kDa complexes, where the difference in transfection levels 
between blank diblock PLGA36kDa-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes WR 1-5  
was between 0.5-fold to 6.4-fold lower than fresh bPEI25kDa/pDNA (N/P 5) complexes 
(Figures 3.9(a) and 3.9(c)), compared to the other two blank triblock micelle systems 
which contained two PLGA blocks each; transfection levels using blank 
micelle/pDNA/bPEI1.8kDa WR 1-5 complexes ranged from 3.7-fold to 71-fold lower than 
fresh bPEI25kDa/pDNA (N/P 5) complexes (Figures 3.9(d), 3.9(f), 3.9(g), and 3.9(i), a much 
broader range than the diblock system.  
The benefit of dexamethasone became obvious after comparing gene expression 
levels achieved using dex-loaded micelle/pDNA/bPEI1.8kDa complexes to control 
reconstituted blank micelle/pDNA/bPEI1.8kDa complexes and reconstituted 
bPEI25kDa/pDNA (N/P 5) complexes. Transfection efficiencies using the diblock copolymer 
(PLGA36kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes did not increase significantly 
using the dex-loaded micelles for weight ratios > 1 (p > 0.29), indicating that the amount 
of dexamethasone present was not enough to further enhance the transfection 
achieved from the bPEI block. However, the presence of dexamethasone significantly 
improved gene transfection efficiency for the triblock polymers, using (PLGA36kDa)2-b-
bPEI25kDa micelle/pDNA/bPEI1.8kDa (p < 0.00001) or (PLGA48kDa)2-b-
bPEI25kDa/pDNA/bPEI1.8kDa complexes (p < 0.0001) from 1.1-fold up to 35-fold higher than 
their blank counterparts. Indeed the most dramatic improvement in gene transfection 
occurred for complexes with WR < 1. All three copolymer systems showed marked 
increase in gene transfection using dex-micelle/pDNA/bPEI1.8kDa WR < 1 complexes 
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compared to blank micelle/pDNA/bPEI1.8kDa WR < 1 complexes: 10.7-fold to 21.9-fold 
higher transfection levels for PLGA36kDa-b-bPEI25kDa /pDNA/bPEI1.8kDa complexes (p < 
0.007) (Figures 3.9(a) and 3.9(b)), 19.6-fold to 32.7-fold higher transfection levels for 
(PLGA36kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes (p < 0.0006) (Figures 3.9 (d) 
and 3.9(e)), and 20.8-fold to 35-fold higher transfection levels for (PLGA48kDa)2-b-
bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes (p < 0.008) (Figures 3.9(g) and 3.9(h)), 
indicating that the presence of dexamethasone was beneficial in enhancing transfection 
levels. This could be very useful as a method to decrease the amount of polymer carrier 
necessary to achieve equivalent gene expression; decreasing the amount of polymer 
administered would also diminish unwanted toxicity resulting from the carrier, making 
these dex-loaded micelle carriers a favorable candidate for enhanced gene delivery to 
the nucleus.  
The appeal of this system becomes even more apparent after comparing 
transfection levels using dex-loaded micelle/pDNA/bPEI1.8kDa complexes and 
reconstituted bPEI25kDa/pDNA (N/P 5) complexes. Gene expression levels ranged from 
30-fold to 44-fold higher using dex-loaded micelle/pDNA/bPEI1.8kDa WR 0.25 complexes 
compared to reconstituted bPEI25kDa/pDNA (N/P 5) complexes, and increased up to 100-
fold higher expression for dex-loaded micelle/pDNA/bPEI1.8kDa WR 1 complexes (Figure 
3.9(a), 3.9(c), 3.9(d), 3.9(f), 3.9(g), and 3.9(i)). Previously we had shown that blank 
(PLGA36kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa WR 1 complexes were able to achieve 
transfection levels 39-fold higher than reconstituted bPEI25kDa/pDNA (N/P 5) complexes. 
Thus the presence of dexamethasone increased expression levels an additional 60-fold 
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higher than the blank system, establishing that nuclear accumulation of polyplexes 
increased with the presence of dexamethasone in the micelle core. As it is known that 
bPEI25kDa is quite sticky and does not reconstitute well following lyophilization, the blank 
(PLGA36kDa)2-b-bPEI25kDa micelle system had already proved to be a vast improvement, 
and the addition of dexamethasone improved the system even further. Curiously, 
transfection efficiency using PLGA36kDa-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa WR 3 
complexes was an astounding 477-fold higher than reconstituted bPEI25kDa/pDNA (N/P 5) 
complexes (Figure 3.9(a) and 3.9(c)). It is apparent that combining the transfection 
enhancement afforded by using reconstituted PLGA-b-bPEI micelle/pDNA/bPEI1.8kDa 
complexes coupled with the presence of dexamethasone in the core greatly increased 
gene transfection efficiency and subsequent gene expression in MCF7 cells.  
It has been shown that the presence of dexamethasone (either as a pre-
treatment or by conjugation) enhances the transfection of genes in cells. 
Dexamethasone binds to the glucocorticoid receptor in the cytosol of the cell, and then 
translocates into the nucleus. This means that if dexamethasone is conjugated onto the 
carrier surface, carrier entry into the nucleus is chaperoned by the dexamethasone-
receptor complex [40]. Dexamethasone alone can also dilate the nuclear pore complex, 
so if cells are pretreated with dexamethasone, the nuclear pore complexes dilated and 
also allowed DNA carriers to enter the nucleus [34, 49]. In our experiments, because 
dexamethaone was loaded into the micelle core, it needed to diffuse out of the core in 
order to dilate the nuclear pore complex. If no enhancement of gene transfection was 
seen, then that would indicate that dexamethasone was not releasing from the micelles.    
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To confirm that this transfection enhancement effect was directly due to the 
presence of dexamethasone, a transfection experiment was conducted where cells were 
treated with blank micelle/pDNA/bPEI1.8kDa complexes and free dexamethasone 
simultaneously and transfection levels were compared to blank micelle/pDNA/bPEI1.8kDa 
complexes only (no dexamethasone treatment). As shown in Figure 3.10, transfection 
efficiency increased with increasing dexamethasone dose, indicating that enhanced 
gene expression correlated directly with the presence of dexamethasone and confirms 
that dexamethasone alone was responsible for the increase in gene transfection, since 
all other conditions remained identical. Interestingly, the amount of dexamethasone 
required to enhance transfection was greater when cells were treated with free 
dexamethasone, and less dexamethasone was required to elicit an equivalent response 
when cells were treated with dex-loaded micelles. These results not only indicate that 
dexamethasone released from the core of the micelle and diffused out into the cytosol 
where it was able to act upon the nuclear pore complexes and enhance nuclear 
accumulation of the polyplexes, but also that the amount of dexamethasone necessary 
to enhance nuclear accumulation was reduced because of the delivery of 
dexamethasone was localized directly within the cell. This is important because 
dexamethasone can sometimes have a negative effect when administered in high doses, 
and by delivering the dexamethasone locally rather than systemically this can alleviate 
any potential unwanted side effects caused by interactions with excess dexamethasone. 
Finally, the toxicity of all three dex-loaded micelle/pDNA/bPEI1.8kDa complexes was 






viabilities greater than 90% at every condition tested (Fig. 3.11), including the condition 
that achieved 3.4-fold higher gene expression than “fresh” bPEI25kDa/pDNA (N/P 5) 
complexes. 
Based on these results, our system has many favorable characteristics that make 
it a good candidate for gene delivery: dex-micelle/pDNA/bPEI1.8kDa complexes can be 
lyophilized and reconstituted without the loss of physicochemical or biological 
characteristics, are relatively nontoxic, achieve equivalent transfection efficiency using 
less polymer compared to the blank carrier alone, and enhance gene transfection 
efficiency by increasing nuclear accumulation of the delivery vehicle. In addition, the 
possibility to customize the carrier even further exists due to the unique structure of 
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this particular copolymer. Conjugating targeting moieties to the carrier surface could 
increase cellular uptake in a particular population of interest, and coupled with the 
increased nuclear accumulation already afforded from dexamethasone, this creates a 
multifunctional dual-agent delivery system that can be lyophilized for storage and easily 
reconstituted for use without losing potency. 
3.5. Conclusions 
 The intent of this study was to create a charged polymeric micelle-based gene 
delivery system that showed enhanced nuclear delivery and increased gene expression. 
Using (PLGA)n-b-bPEI25kDa block copolymers to create micelles loaded with 
dexamethasone in the core, we were able to create a stable micelle system that 
retained its physicochemical characteristics following reconstitution and successfully 
transfected breast cancer cells with a reporter gene to achieve relatively high gene 
expression levels with minimal cytotoxicity. Transfection efficiency was enhanced by the 
presence of dexamethasone in the micelles, which increased nuclear accumulation of 
the polyplexes and subsequent gene expression. Finally, this system could be useful in 
reducing carrier-induced toxicity by decreasing the amount of polymeric carrier 
necessary to achieve equivalent gene transfection since dexamethasone was able to 
increase nuclear accumulation of the polyplexes. The results from this system are 
encouraging in the quest to develop nonviral carrier systems for gene therapy 
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4.1. Synopsis of Results and Conclusions 
 
 Current nonviral based gene delivery vehicles are plagued by low gene 
transfection and gene expression rates, and many formulations are not well-suited for 
use in a clinical setting. The purpose of this research was three-fold: to create a 
polymeric micelle-based delivery system that could be co-loaded with two different 
therapeutic molecules, to demonstrate that these micelles system could also be used 
for gene therapeutics delivery and would retain efficacy following lyophilization and 
reconstitution, and finally that the co-loaded micelle system could preferentially 
accumulate in the cell nucleus, thereby increasing gene transfection and subsequently 
gene expression.  
A cationic copolymer synthesized by conjugating poly(lactide-co-glycolide) 
(PLGA) and branched polyethylenimine (bPEI) was used to form charged polymeric 
micelles with a core-shell architecture which were investigated for nonviral gene 
therapeutics delivery. The copolymer was designed to utilize the proton-buffering ability 
and high transfection efficiency of bPEI combined with decreased overall cytotoxicity 
and the ability to load hydrophobic drugs in the micelle core conferred by the PLGA 
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block. The resulting micelles retained their physicochemical characteristics following 
lyophilization and reconstitution, and the bPEI25kDa block retained about 65% of its 
proton buffering capacity following copolymerization.  
Micelle/pDNA complexes were also evaluated for changes in their 
physicochemical and biological characteristics of following lyophilization and 
reconstitution. Polyplexes retained their particle size and zeta potential following 
reconstitution. Adding a small amount of bPEI1.8kDa completely shielded pDNA in the 
complexes and transfection efficiency was enhanced 50-100 fold without affecting 
complex size. Reconstituted micelle/pDNA/bPEI1.8kDa WR1 complexes achieved 16-fold 
higher transfection rates compared to their fresh counterparts, and although 
transfection levels were slightly lower (3.9-fold) than control fresh bPEI25kDa/pDNA (N/P 
5) complexes, transfection levels were nearly 40-fold higher than reconstituted 
bPEI25kDa/pDNA (N/P 5) complexes. Finally, the micelle/pDNA/bPEI1.8kDa system had very 
low toxicity even with pDNA doses up to 20µg, and transfection levels increased linearly 
with increasing pDNA dose. This study concluded that this PLGA-b-bPEI micelle-based 
system was well suited as a reconstitutable gene delivery system and could be useful as 
a delivery system in gene therapy applications in the future.  
Having confirmed that this copolymer architecture and the resulting micelles 
were reconstitutable and suitable for gene therapeutics delivery, the next step was to 
determine whether the system could be co-loaded with two different therapeutic 
molecules and if this system could be used to enhance nuclear accumulation of the gene 
carrier. Several different copolymers having a PLGA-b-bPEI architecture were 
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synthesized, characterized, and used to make polymeric micelles: PLGA36kDa-b-bPEI25kDa 
diblock copolymer, (PLGA36kDa)2-b-bPEI25kDa triblock copolymer, and (PLGA48kDa)2-b-
bPEI25kDa triblock copolymer. Micelles were loaded with dexamethasone during 
formation, and the resulting dex-loaded micelles were characterized in terms of particle 
size, zeta potential, dexamethasone content, proton buffering capacity, and 
reconstitutability. Dex-loaded micelles were then complexed with pDNA and evaluated 
for particle size, zeta potential, pDNA condensation ability, and cell transfection 
efficiency.  
As expected, all three dex-loaded micelle systems retained their particle size and 
zeta potential characteristics following reconstitution, forming micelles that were 70-
100nm in diameter and strongly positive zeta potential (35-45mV). Proton buffering 
capacity was also retained in all three copolymer systems although buffering capacity 
decreased following copolymerization (ranging from 32% to 72% compared to free 
bPEI25kDa alone), and was affected by both the molecular weight and block ratio of PLGA 
contained in the copolymer; proton buffering capacity decreased as the number of PLGA 
blocks increased, and as the molecular weight of the PLGA block increased. The amount 
of dexamethasone incorporated into the micelle core varied from 7.6 wt% to 17.4 wt% 
as determined by UV spectroscopy. The dex-loaded micelle systems had very low 
cytotoxicity overall and toxicity was unaffected by the presence of dexamethasone.  
Dex-loaded micelles were complexed with pDNA and then mixed with bPEI1.8kDa 
to form dex-micelle/pDNA/bPEI1.8kDa complexes and characterized for particle size, zeta 
potential, pDNA condensation, transfection efficiency, and cytotoxicity. Polyplexes also 
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retained their particle size and zeta potential following reconstitution, and reconstituted 
complexes were used for all further experimentation. Transfection efficiencies using 
dex-micelle/pDNA/bPEI1.8kDa complexes were compared to blank 
micelle/pDNA/bPEI1.8kDa complexes, fresh bPEI25kDa/pDNA (N/P 5) complexes and 
reconstituted bPEI25kDa/pDNA (N/P 5) complexes. Transfection levels ranged from only 
1.4-fold to 4.8-fold lower than fresh bPEI25kDa/pDNA (N/P 5) complexes, even for 
polyplexes with WR < 1. In fact, using PLGA36kDa-b-bPEI25kDa dex-micelle/pDNA/bPEI1.8kDa 
WR 3 complexes transfection levels were 3.3-fold higher than fresh bPEI25kDa/pDNA (N/P 
5) complexes. In contrast, transfection levels using blank micelle/pDNA/bPEI1.8kDa WR 1 
complexes were between 1.4-fold up to 8.1-fold lower than fresh bPEI25kDa/pDNA (N/P 
5) complexes. Thus loading dexamethasone into the micelle core reduced the amount of 
polymer necessary to achieve equivalent transfection levels by up to 4-fold.  
The benefits stemming from the presence of dexamethasone were apparent 
after comparing transfection levels achieved using dex-loaded micelle complexes and 
blank micelle complexes, and even more so after comparing transfection levels from 
dex-loaded micelle complexes to reconstituted bPEI25kDa/pDNA (N/P 5) complexes. Dex-
loaded micelle/pDNA/bPEI1.8kDa systems achieved expression levels ranging from 1.1-
fold up to 35-fold higher than their counterpart blank micelle/pDNA/bPEI1.8kDa 
complexes. All three copolymer systems showed marked increase in gene transfection 
using dex-micelle/pDNA/bPEI1.8kDa WR < 1 complexes compared to blank 
micelle/pDNA/bPEI1.8kDa WR < 1 complexes: 10.7-fold to 21.9-fold higher transfection 
levels for PLGA36kDa-b-bPEI25kDa /pDNA/bPEI1.8kDa complexes (p < 0.007), 19.6-fold to 
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32.7-fold higher transfection levels for (PLGA36kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa 
complexes (p < 0.0006), and 20.8-fold to 35-fold higher transfection levels for 
(PLGA48kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa complexes (p < 0.008), indicating that 
the presence of dexamethasone was beneficial in enhancing transfection levels. This 
could be very useful as a method to decrease the amount of polymer carrier necessary 
to achieve equivalent gene expression; decreasing the amount of polymer administered 
would also diminish unwanted toxicity resulting from the carrier, making these dex-
loaded micelle carriers a favorable candidate for enhanced gene delivery to the nucleus.  
The most exciting results were obtained in comparing expression levels using 
dex-loaded micelle/pDNA/bPEI1.8kDa systems to reconstituted bPEI25kDa/pDNA (N/P 5) 
complexes. All three dex-loaded micelle/pDNA/bPEI1.8kDa WR 0.25 complexes had 
expression levels 30- to 44-fold higher than reconstituted bPEI25kDa/pDNA (N/P 5) 
complexes, and increased up to 100-fold higher using dex-loaded 
micelle/pDNA/bPEI1.8kDa WR 1 complexes. Previously we had shown that blank 
(PLGA36kDa)2-b-bPEI25kDa micelle/pDNA/bPEI1.8kDa WR 1 complexes were able to achieve 
transfection levels 39-fold higher than reconstituted bPEI25kDa/pDNA (N/P 5) complexes. 
Thus the presence of dexamethasone increased expression levels over 60-fold higher 
compared to the blank system, clearly establishing that nuclear accumulation of 
polyplexes increased with the presence of dexamethasone in the micelle core. Finally, 
the toxicity of the dex-loaded micelle/pDNA/bPEI1.8kDa complexes was significantly lower 
than “fresh” bPEI25kDa/pDNA (N/P 5) complexes, with cell viabilities greater than 90% at 
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every condition tested, including the condition that achieved 3.4-fold higher gene 
expression than “fresh” bPEI25kDa/pDNA (N/P 5) complexes.  
In conclusion, cationic PLGA-b-bPEI copolymers were synthesized and used to 
create charged polymeric micelles for targeted nuclear delivery of gene therapeutics. 
This system demonstrated several advantages over current polymer carriers due to their 
reconstitutable nature and enhanced nuclear accumulation, leading to increased gene 
expression while decreasing carrier requirements. These PLGA-b-bPEI copolymers were 
significantly less toxic than traditional bPEI25kDa control while achieving nearly equivalent 
or higher expression of a reporter gene in vitro. The advantage of this particular micelle-
based system is that the micelle architecture can be utilized for the co-delivery of two 
different therapeutics simultaneously and shows enhanced nuclear accumulation and 
gene transfection which is particularly important for gene therapy applications. The 
results presented using this system demonstrate positive progress towards improving 
nonviral polymeric carriers as effective delivery systems for gene therapy.  
4.2. Future Directions 
Initial characterization of the PLGA-b-bPEI copolymer system indicated that this 
cationic micelle system shows promise as a nonviral vector for gene delivery 
applications. However, further optimization and experimentation remain in order to 
determine the full therapeutic potential of this carrier system. Having thoroughly tested 
this system using a reporter gene, the next phase should include delivery and evaluation 
of gene expression using therapeutically relevant genes. Optimizing the block copolymer 
architecture in terms of block ratio and block molecular weight to determine maximum 
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drug carrying capacity will influence the suitability of this system for treating different 
disease models. Examining carrier behavior and transfection efficiency in different cell 
types, modifying the carrier to selectively accumulate in other target populations, 
investigating whether reconstitution characteristics extend to protect more sensitive 
drug cargo such as protein drugs all would serve to elucidate the potential use of this 
micelle system for gene therapy applications.  
4.2.1. Combination Therapy to Treat Inflammatory Diseases 
Glucocorticoid receptors are ubiquitous to nearly every cell type in the body. 
They are usually located in the cytoplasm and upon binding to glucocorticoid hormones 
the ligand-receptor complex will translocate into the nucleus through channels formed 
by nuclear pore complexes. The glucocoricoid receptor can bind directly to DNA to 
control gene transcription, or it can bind other proteins to signal gene transcription. 
Glucocorticoids are involved in the regulation of carbohydrate, protein and fat 
metabolism [1], modulation of immune responses by suppressing chemokine and 
cytokine production [2, 3], and serve important roles in the central nervous system [4, 
5], digestive system [6], renal system [7], hematopoetic system [8] and the reproductive 
system [9].   
Dexamethasone is a synthetic steroid hormone that can bind to the 
glucocorticoid receptor in the cytosol to form a receptor-ligand complex. This complex 
can serve as a transcription factor by binding to the promoter region of a gene to 
stimulate gene expression. It has been shown to have enhancing and suppressing effects 
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on transgene expression in vitro, indicating that this molecule could be important to 
achieving successful gene therapy [10]. 
Dexamethasone can also act as an anti-inflammatory and an 
immunosuppressant, and these properties have made it useful in the clinic as a 
secondary treatment to alleviate some of the side effects resulting from chemotherapy 
by suppressing cytokine production. By utilizing both these features, our dex-loaded 
micelle system could be used to deliver both dexamethasone and DNA/RNA 
simultaneously. This combination therapy approach could benefit people suffering from 
diseases that already require and respond to anti-inflammatory treatment such as 
asthmatic patients; delivering dexamethasone at the site of interest would increase the 
local concentration and allow better control of symptoms, and also decrease the 
possibility of developing glucocorticoid resistance which is common in patients requiring 
chronic glucocorticoid treatment. The efficacy of dex-loaded micelles could be evaluated 
using cell models that mimic conditions in asthmatic patients to determine whether 
lower concentrations of dexamethasone (as present in the micelles) would alleviate 
symptoms to the same degree, and whether the co-delivery of DNA could transfect the 
cells with genes that would also have an anti-inflammatory effect for stronger 
treatment. This technology could then be extended further to encompass other diseases 
that already use dexamethasone treatment.  
4.2.2. In Vivo Efficacy Studies Using Dexamethasone-Loaded Micelles 
 Our characterization of the charged catinonic polymer-based dexamethasone-
loaded micelle system for gene delivery was conducted in vitro using a cancer cell 
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model. Given the encouraging results in transfection enhancement due to the presence 
of dexamethasone, the next logical step would be to further evaluate this system in vivo 
which would enable us to determine whether the beneficial effects seen during the in 
vitro characterization are retained in a more realistic model environment. Because anti-
inflammatory treatment is often administered to cancer patients, it would be of value to 
evaluate whether there is any anti-inflammatory therapeutic benefit from the 
dexamethasone in addition to its current role for transfection enhancement. Using DNA 
that codes therapeutically relevant genes such as anti-inflammatory genes would 
provide an additional layer of therapeutic benefit to the patient, creating a 
combinatorial anti-inflammatory treatment option which could be more effective than 
the current single-treatment approach of systemically administering anti-inflammatory 
drugs.  
4.2.3 Delivery of siRNA 
 Ongoing research is increasingly discovering that many disease conditions are 
caused by changes in protein expression levels in the body. This can be due to increased 
expression, decreased expression, or the expression of mutant/misformed proteins. 
Altering protein expression by interfering with gene translation using RNA has become 
an active area of interest for altering disease progression. The delivery of small 
interfering RNA molecules (siRNA) against particular genes has been shown to be quite 
effective at reversing some disease states. Due to the nature of our micelle-based 
delivery system, instead of DNA, RNA molecules could easily be loaded by complexation 
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and delivered to the cells of interest with higher accumulation, which could result in 
more effective silencing because of increased interference in gene expression.  
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INCREASING INSULIN SECRETION IN ENCAPSULATED ISLETS 
 





Donor scarcity is one problem affecting islet transplantation, due to huge islet 
requirements for patient insulin-independence (>10,000 islets/kg body weight). 
Increasing insulin output from pancreatic islets in response to elevated glucose levels 
using peptide stimulants such as Exendin-4 could decrease the number of islets required 
to achieve normoglycaemia. Exendin-4 was conjugated to poly(vinyl pyrrolidone-co-
acrylic acid) using a PEG3400 spacer (VAPE). Conjugation was confirmed using RP-HPLC. 
Exendin-4 content in VAPE was determined to be 30 wt% using UV spectroscopy. 
Following a glucose challenge test, insulin secretion from the islets was quantified using 
radioimmunoassay techniques. When glucose levels were changed from 2.6mM (basal 
level) to 16.8mM (elevated level), insulin secretion increased 300% (p=0.00009) when 
VAPE stimulant was present compared to the control (no stimulant). Insulin secretion 
levels were not amplified at lower glucose levels (2.6mM-5.8mM) (p=0.87), the 
stimulatory effect was seen only at higher glucose levels (16.8mM). Insulin secretion 
levels were comparable when islets were stimulated with either Exendin-4 peptide or 
Exendin-4/polymer conjugate (p=0.93) using equivalent concentrations ranging from 
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1nM to 1uM, indicating there was not a dramatic loss of bioactivity caused by 
conjugation. When islets were encapsulated with Exendin-4/polymer conjugate, islets 
maintained steady levels of insulin secretion in response to cyclic changes in glucose 
concentrations over two weeks, indicating continued islet functionality and 
responsiveness over time. This Exendin-4/polymer conjugate could be useful in 
decreasing the number of islets required for transplantation by increasing insulin output 
from pancreatic islets in response to elevated glucose levels.  
A.2. Introduction 
 
Diabetes Mellitus is a disease which occurs when the body is no longer able to 
properly produce or utilize insulin.  Although the actual cause of diabetes is still not 
properly understood, it is believed that disease development is influenced both by 
environmental factors and genetics.  There are two major classes of diabetes mellitus, 
Type I and Type II, as well as gestational diabetes and prediabetes.  Type I patients 
account for approximately 10% of the diabetic population, while Type II patients 
account for the other 90%.  According to the Center for Disease Control, diabetes was 
listed as the sixth leading cause of death in 2002 [1] . There are approximately 21 million 
people with diabetes in the United States, and an estimated 177 million diabetic 
patients worldwide [2].  In 2005, 1.5 million new cases of diabetes were diagnosed.  
Annual costs per patient range from $1,000 to $15,000, and in 2002 it was reported that 
total diabetes-related expenditures amounted to $132 billion.  It is estimated that by 
the year 2025, there will be more than 300 million people worldwide suffering from 
diabetes [1-4].  
164 
 
Type II diabetic patients retain the ability to produce insulin, and can often 
control their disease state through diet and exercise. However, patients suffering from 
Type I diabetes have lost the ability to produce insulin because their beta cells have 
been destroyed. Although there are several different treatment options available to 
Type I patients, the most commonly prescribed treatment is exogenous insulin 
administration. Thus, they must rely on repetitive insulin injections or infusions to 
control their blood sugar, and the success of this treatment is dependent upon patient 
compliance.  
Current treatment options for this group are limited to whole pancreas or islet 
transplantation, administration of exogenous insulin, mechanical artificial pancreas 
transplant, and bioartificial pancreas transplant. Pancreas transplants are limited as a 
treatment option because of the scarcity of donor organs. Administering exogenous 
insulin is currently the most common treatment option, although it relies very heavily 
on patient compliance in order to be effective. In an effort to improve the quality of life 
for Type I patients, there has been a major effort to create a ‘bioartificial pancreas’ 
system to replace the lost insulin-producing function of the islets, thereby eliminating 
the need for multiple daily insulin injections. Research groups have investigated the use 
of systems made from hollow-fiber membranes [4, 5], genetically modified/altered islets 
or naked islets [6-9], stem-cells [10, 11], and encapsulation systems [12-15]. Extensive 
research has been done using encapsulation systems based on alginate and/or poly-L-
lysine membranes, showing capsule stability and islet functionality for years [15-19]. 
Microencapsulation systems have several beneficial features including islet 
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immunoprotection through a semipermeable membrane [20], smaller implant volume 
[21], and easily accessible implantation sites [21-23]. For these reasons, a 
microencapsulation system was chosen for this research application. Islets were 
encapsulated in a five-layer membrane double-wall design consisting of alternating 
layers of alginate and poly-L-lysine, shown as a schematic in Figure A-1. 
Current guidelines suggest that 15,000 islets or islet equivalents should be 
implanted per kilogram of body weight [24-26]. There is a shortage of readily available 
islets due to the scarcity of pancreas donors, so any methods that decrease the number 
of islets required to achieve and maintain normoglycemia would be advantageous. One 




Figure A-1: Schematic of encapsulated islets 
  
Figure 1: Capsule Schematic 
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secretion from the islets. One candidate molecule is glucagon-like peptide 1 (GLP-1), a 
small hormone which signals the production of insulin in islets in response to high blood 
glucose levels, and exendin-4, a GLP-1 analog.  GLP-1 is one of the products produced 
from the preproglucagon gene, synthesized mainly by enteroendocrine L cells of the 
intestine [27-30].  It is a small peptide with a molecular weight of 3348 Daltons [29] 
whose most important action is the stimulation of insulin production in response to 
glucose. This molecule in particular responds to very high glucose levels in the body, 
greater than 3mM glucose levels [31], which is why it is ideal for treating Type I diabetes 
patients.  Other molecules such as sulfonylureas respond at lower glucose levels, making 
them less ideal for treating Type I diabetics [32].  Fasting glucose levels for Type I 
diabetes patients are typically within that range, causing constant stimulation from the 
sulfonylureas, thus these molecules are typically used for treating Type 2 diabetes.   
Some other actions of GLP-1 include inhibition of gastric emptying and glucagon 
secretion, control over feelings of satiety and hunger, several glucose lowering actions, 
and even the regulation of islet regeneration and islet neogenesis [33-36].  
Another candidate molecule is Exendin-4, a small peptide isolated from the 
saliva of the Gila Monster Helodermas suspectum. The pancreatic activity of the 
monster venom was first discovered in 1982 [37], and sequencing and purification 
yielded two molecules: exendin-4 and helodermin [38, 39].  Exendin-4 contains 53% 
homology with mammalian GLP-1, shows high affinity binding to the mammalian GLP-1 
receptor, and nearly equal potency and efficacy in stimulating cAMP production 
compared to mammalian GLP-1 [40-42]. In addition, it is more resistant to enzymatic 
167 
 
degradation in the body, resulting in a longer plasma circulation half-life. However, it 
also has a low molecular weight, 4187Da [38], meaning it too would rapidly diffuse out 
of the capsules and become lost into systemic circulation. Because of its increased 
potency over GLP-1, it was modified to create a formulation which would increase its 
retention within the microcapsules, and provide a depot of peptide to the islets.    
A.2.1. Type I Diabetes Mellitus 
Type 1 Diabetes Mellitus, formerly known as ‘juvenile diabetes’ or ‘insulin-
dependent diabetes mellitus (IDDM)’, constitutes about 10% of the patients diagnosed 
with diabetes [43]. It is characterized by the systematic destruction of β-cells in the 
pancreas by the host’s immune system, leading to a dependence on exogenous insulin 
sources to control blood glucose levels [44]. Patients typically have to check their blood 
glucose levels several times a day using a glucometer and then administer the 
appropriate amount of insulin into their system, usually via an injectable form.    
A.2.1.1. Pathology of Type I Diabetes  
 Type I diabetes results from the destruction of β-cells in the pancreas by the 
immune system. The loss of these cells means the body can no longer produce insulin, 
resulting in elevated glucose levels in the blood. Over time, higher blood glucose levels 
lead to serious health complications such as diabetic neuropathy, diabetic retinopathy, 
kidney disease, diabetic ketoacidosis, cardiac problems (i.e., heart disease and stroke), 
and even death [45-50]. Disease progression can be retarded by rigorously controlling 
cholesterol, blood pressure, and blood lipids. Most importantly, blood sugar levels can 
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be monitored and maintained through the careful administration of insulin. However, 
this means that the patient must check their blood glucose levels through a finger prick 
and then self-administer the necessary amount of insulin through an injection several 
times a day. This process is very painful and inconvenient for the patient, and does not 
preclude the development of complications. In addition, miscalculation of insulin 
requirements by the patient can pose serious health risks.   
A.2.1.2. Current Treatment Options  
At the present time, there is no cure for Type I diabetes. However, several 
options exist to help patients manage their disease. One option is to have a whole organ 
transplant, replacing the diseased pancreas with a donor pancreas [51]. This is difficult 
due to the general scarcity of organs and cost ($125,800 + $6900 per followup visit [52]). 
If a patient receives an organ transplant, there is a high chance the organ could be 
rejected, or blood clots could develop within the pancreas and the tissue would die from 
necrosis. In addition, the patient’s pancreas is usually completely functional except for 
insulin production, so with the addition of the new pancreas there is 
overproduction/overexpression of some enzymes in the body, which can lead to other 
problems such as urinary tract infections, hyperinsulinemia, metabolic acidosis, 
hematuria, and reflux pancreatitis [53-56].     
The most common treatment is exogeneous insulin administration through 
multiple daily injections, an insulin pump, or using an inhalable insulin form. Patients 
need to monitor their blood sugar levels several times a day using a glucose monitor and 
administer insulin accordingly. This procedure is quite painful, requiring needle sticks to 
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obtain blood for the glucose meter and injections to administer insulin. If a patient uses 
a continuous infusion insulin pump, they might still require booster insulin shots around 
mealtime. These methods of insulin administration are not perfect, and patients can 
easily misjudge the amount of insulin they require. This can cause any number of 
complications; if they administer too much insulin and cause their blood sugar to 
plunge, they can become disoriented and go into shock. If they administer too little, 
then their blood sugar will remain very high for too long, causing damage to sensitive 
tissues such as the eyes [57-59].   
Another option is the implantation of an artificial pancreas, sometimes called a 
mechanical artificial pancreas. This device consists of three parts: a glucose sensor, an 
insulin pump, and a computer. The problem with this type of device is that a stable and 
accurate glucose sensor has yet to be developed, and an error in delivery or sensing 
could be quite risky, causing hypoglycemia or worse [60-64]. The mechanical pancreas 
also does not respond to changes in glucose as rapidly as islets, which can detect 
changes in less than 10 minutes [65]. These complications have led many researchers to 
look for an alternative solution to create a bioartificial organ to replace and mimic the 
natural system as closely as possible, improving overall quality of life and allowing these 
patients to resume a lifestyle similar to people without diabetes. Using a bioartificial 
system is beneficial because it replicates only the endocrine functions of the pancreas, 
which is the functionality lost when the islets of Langerhans are destroyed. This system 
provides the ability to monitor and sense changes in glucose levels rapidly. This 
treatment option also bypasses the need to administer immunosuppressive drugs to the 
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patient, thus avoiding potential side effects and complications associated with 
immunosuppression [66]. Various bioartificial pancreas systems currently under 
investigation are described in the next section, and summarized in Table A1.   
A.2.2. Bioartificial Pancreas Systems 
There are several artificial pancreas systems currently under development by 
various groups. Different approaches include implanting hollow fiber membranes filled 
with islets/cells [4-6], implanting microcapsules containing islets/cells within 
immunoprotective membranes [12-15], directly injecting naked islets [9, 10], implanting 
genetically modified islets [7, 8], and implanting stem cells [11, 12]. The intended 
implantation site impacts the type of approach used for the artificial system. Implanting 
cells or islets directly is usually done through the portal vein in the liver, where there is 
an adequate continuous supply of nutrients and direct access to the digestive system 
[24, 67]. Capsules or hollow fiber membrane systems are typically implanted in the 
peritoneal cavity [68-70]. Using an encapsulation system provides the advantage of 
immunoprotection of the islets through the capsule membrane. The molecular weight 
cutoff of the membrane can be controlled by manipulating the conditions of capsule 
manufacture so it is impermeable to the immunoglobulins and other molecules 
produced during an immune response [71]. It has been shown that implanted alginate-
poly-L-lysine microcapsules are very well tolerated in the body [72]. In addition, the use 
of xenogenic islet sources within the encapsulation system did not require any 
immunosuppression regimens in the patients. The encapsulation membrane was 






Ta ble AI: Types of Art if icial Pa ncreas Systems 
Artificial Pancreas System Advantages Disadvantages 
Provide local ext racel lular Hollow fiber membranes could 
Macrocapsule Systems such as Hollow environmen t to support islet s, become encapsula ted by fi brous 
Fiber Membranes [5, 6) anchors islets wi thin a specific t issue, t rigger immune responses, 
area to con trol insulin delivery degrada t ion products could cause 
secondary immune react i ons 
Some risks when using viral vectors 
Genet icall y Al tered Isle ts [7,8] Abil ity to figh t apoptosis, perhaps for t ransfect ion, and very low 
st imula te local angiogenesis t ra nsfect ion efficiency using 
non -viral gene vectors 
Naked Islets [9, 10] Impla nted in to the portal vein, able to Readil y accessible to attack by 
restore normogl ycemia the host immune system 
Can be st imula ted to differen t iate This p rocess takes t ime, and is not into islet -like cells which are able 
Stem Cells [11, 12] to produce insulin, produced from always a viable option depending 
the patient's own cells on t he patient's heal th status 
Immunoisolated system, does not 
Microcapsule Systems such as algina te-
req u ire immunosuppresion, allows Some biocompa t ibili ty issues if 
the use of xenogenic cells, poly-L-Iysine is used and there is 
PLL capsules [13-15] physically separates cell s from in complete complexat ion 
the host immune syst em 
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Based on the literature, encapsulation systems comprised of alginate and poly-L-
lysine have been used quite extensively, and are biocompatible in animals and humans 
for years [21].  For this reason, an alginate-poly-L-lysine microcapsule system having a 
five-layer membrane composed of alternating layers of alginate and poly-L-lysine was 
selected. The molecular weight of the poly-L-lysine dictates the molecular weight cutoff 
(MWCO) of the membrane. The cut-off value can be modified by several factors 
including varying the molecular weight of the poly-L-lysine or changing the incubation 
time [18]. The MWCO for this system is 100,000 Daltons, selected because this pore size 
is large enough to promote free exchange of oxygen, nutrients, and insulin but prevents 
large antibodies (150kDa – 900kDa [74]) from accessing the islets. Although it has been 
suggested that this MWCO may not be sufficient for protection [75], studies have shown 
that although there may be some permeation into alginate capsules in vitro, the 
capsules may be xenoprotective in vivo [76]. The core of the capsule will be liquefied so 
that the islets are mobile within the capsule, rather than being immobilized within a 
matrix. These conditions are similar to culture conditions in vitro in media without the 
capsule present. This system will protect the islets from the host immune system 
because the physical barrier of the membrane and its molecular weight cutoff prevent 
immune components from accessing the islets. The immuoprotection afforded by the 
membrane eliminates the need for immunosuppressive drug regimens, which create a 




A.2.3. Alginate/Poly-L-Lysine Microcapsules 
Alginate has been shown to be relatively biocompatible [20, 21], and for this 
application an ultrapure low viscosity mannuronic acid alginate was used.  Poly-L-lysine 
(PLL) affects the permeability of the membrane; changing the molecular weight of the 
PLL controls the molecular weight cutoff of the entire membrane.  For this application, 
PLL with a molecular weight 10,000-20,000Da was selected to give a molecular weight 
cutoff around 100kDa for the capsule membrane. Goosen et al. [19] demonstrated that 
several properties of these microcapsules including shape, permeability, and size can be 
controlled. It has also been shown by Sun et al. [79] that transplanting islets immobilized 
in alginate-poly-L-lysine capsules is an effective way to treat diabetes. Double-wall 
membrane capsules are functionally superior to single-wall membrane capsules, 
forming fewer deformed capsules during microcapsule preparation [80]. Capsules 
implanted into the peritoneal cavity have been shown to be stable and yield viable islets 
upon retrieval several months/years after the initial implantation [81-86].  Using 
microcapsule systems allows the inclusion of cells from xenogenic sources, and due to 
their smaller size, implantation is easier in a murine diabetes model.  For these reasons, 
the alginate/poly-L-lysine microcapsule system has been selected for this bioartificial 
pancreas application.   
A.2.3.1. Alginate 
Alginate is a naturally occurring polymer that exists in brown seaweeds and 
bacterium whose composition varies depending on the source of isolation [87, 88]. 
Alginates are unbranched binary copolymers with widely varying compositions and 
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structures. The two components of alginates are β–D-mannuronic acid (M) and α– L-
guluronic acid (G). The composition and sequential structure of the alginate has a large 
effect on the stability, biocompatibility, and integrity of the alginate capsules formed 
[89-91]. It has been shown that when an outer coating of polycation such as Poly-L-
lysine is applied to alginate microcapsules, intermediate-G or low-G alginates form more 
stable junctions than high-G alginates [89, 91]. The alginate selected for use in this 
application is an ultrapure low viscosity high mannuronic acid alginate, i.e., low-G 
content.   
A.2.3.2. Poly-L-Lysine 
In order to create a selectively porous membrane, polycations are often 
complexed to the alginate layers of microcapsules. The most commonly used polycation 
is poly-L-lysine, although other molecules have also been used including polymers of 
arginine, mixtures of lysine and arginine, and polyorthinine [21]. Poly-L-lysine is a highly 
positively charged amino acid chain, and is commonly used in encapsulation to control 
the molecular weight cutoff of the capsule membrane [85, 92, 93]. Because poly-L-lysine 
has been shown to elicit strong immune responses in the body, it is usually sandwiched 
between layers of alginate to improve biocompatibility of the final biomaterial [94].   
A.2.4. Insulin Secretion 
Insulin secretion is stimulated mainly by glucose, but can also be stimulated by 
the presence of free fatty acids or small peptides such as glucagon-like peptide-1. When 
glucose levels rise in the body, cells begin to metabolize the glucose. This alters the ratio 
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of ATP to ADP in the cell, leading to the closure of ATP-sensitive potassium channels and 
depolarization of the cell. Cell depolarization causes the opening of voltage-gated 
calcium channels, increasing cellular calcium levels. The calcium influx causes the 
activation of protein kinases, which triggers the release of insulin outside the cell 
through exocytosis. The activation of protein kinases can also be achieved by two other 
methods; the metabolism of free fatty acids into long chain fatty acyl moieties or the 
binding of molecules to the GLP-1 receptor. When molecules bind to the GLP-1 receptor 
on the cell surface cAMP levels in the cell are upregulated, leading to the activation of 
protein kinases and subsequent exocytosis of insulin [95]. These processes are 
diagrammed in Figure A-2. 
A.2.5. Glucagon-like Peptide 1 (GLP-1) 
Glucagon-like peptide 1 (GLP-1) is a 30 amino acid peptide derived from 
proglucagon [96]. Its secretion from L-cells in the intestine is stimulated by intraluminal 
glucose levels [29, 34, 97]. The biologically active molecule is GLP-1(7-36) amide, which 
is formed by cleavage and amidation of GLP-1(PG(78-107)) [98]. The molecular weight of 
the peptide is 3348Da, its plasma half-life is about 5 minutes, and its metabolic 
clearance rate is about 12-13 minutes [29, 34]. In the body GLP-1 is rapidly degraded by 
the enzyme dipeptidyl peptidase IV, becoming the biologically inactive GLP-1(9-36 
amide) following the cleavage of its two N-terminal amino acid residues [29].   
GLP-1 functions after binding to its cell surface receptor. GLP-1 receptors are 






Figure A-2: Causes of insulin secretion from cells (adapted from ref [95]) 
 
detectable in the brain, liver, skeletal muscle, adipose tissue, and kidney [98]. GLP-1 
stimulates the production of insulin after binding to its receptor, triggering the 
formation of cAMP [99-101]. This leads to a sequence of events involving the 
phosphorylation of proteins and the activation of cAMP-dependent protein kinase, 
which control insulin secretion [99].   
In addition to stimulating glucose-sensitive insulin production, GLP-1 is known to 
decrease/inhibit glucagon production [29, 34, 102-104], inhibit gastric motility [35, 36], 
and control feelings of satiety/hunger by inhibiting food intake [105-108]. Recent 
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studies also indicate that GLP-1 may indirectly promote the expansion of the β–cell mass 
[109-112].  Of particular interest is GLP-1’s ability to stimulate the production of insulin 
in response to elevated glucose levels. This peptide is only active after the ingestion of a 
meal, when glucose levels rise very rapidly.  This mechanism will boost the amount of 
insulin secreted by islets in addition to what they would normally produce in response 
to rising glucose levels. In addition, it may provide some benefit in maintaining islet 
health over time by promoting β-cell regeneration.   
A.2.6. Exendin-4 
Exendin-4 is a small 39-amino acid peptide (4187Da) isolated from the saliva of 
the Gila Monster Helodermas suspectum [38]. The venom from this lizard was noted to 
have pancreatic secretagogue effects in 1982 [37]. Through sequencing and purification 
of the venom, two peptides were discovered to be responsible for this phenomenon – 
helodermin and exendin-4. Exendin-4 contains 53% homology with mammalian GLP-1 
(Figure A-3) and has been shown to bind with very high affinity to the GLP-1 receptor. It 
is also capable of stimulating cAMP production with equivalent efficacy and potency 
compared to mammalian GLP-1 [40]. Exendin-4 and GLP-1 stimulate other biological 
responses with similar efficacy, such as insulin secretion from β-cells in islets [41, 42]. 
Because its amino acid sequence is somewhat different from GLP-1, it is more resistant 
 
        GLP-1     HAEG-TFTSD-VSSYL- EGQAA-KEFIA-WLVKG-RG 
Exendin-4     HGEG-TFTSD-LSKQM-EEEAV-RLFIE-WLKNG-GPSSG-APPPS 
 




to enzymatic degradation in the body, leading to an increased half-life of 2.4 hours 
following subcutaneous injection [113].  
Exendin-4 has been found to be useful for type II diabetic patients, because it 
improves beta-cells’ sensitivity to insulin [41] and was recently approved by the FDA for 
use as a treatment option for Type II diabetic patients to provide glycemic control in 
patients who are taking metformin, sulfonylurea, or a combination of both [113].  
Marketed under the name BYETTA™, it is the first in a class of drugs known as incretin 
mimetics developed by Amylin Pharmaceuticals, Inc. and Eli Lilly and Company [113].   
A.3. Materials and Methods 
A.3.1. Materials 
A heterobifunctional ω-amino-α-carboxyl poly(ethylene glycol) (PEG; MW 3400; 
HCl · NH2–PEG3400–COOH) was purchased from Shearwater Polymers (Huntsville, AL). 
Exendin-4 was purchased from American Peptide Co. (Sunnyvale, CA). Dimethyl 
sulfoxide (DMSO), dimethyl formamide (DMF), triethylamine (TEA), anhydrous ether, 
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), Hank’s Balanced Saline 
Solution without calcium and magnesium (HBSS), Hank’s Balanced Saline Solution 
(HBSS), Sodium Chloride, Collagenase type V, Ficoll type 400-DL, D-Glucose, sodium 
bicarbonate (NaCHO3), bovine serum albumin, RPMI 1640 medium powder, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt (HEPES), sodium phosphate 
dibasic (Na2HPO4), ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
tetrasodium salt (EGTA), potassium phosphate monobasic (KH2PO4), magnesium 
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chloride hexahydrate (MgCl2 · 6H2O), potassium chloride (KCl), calcium chloride (CaCl2), 
zinc chloride (ZnCl2), and phosphate buffered saline (PBS) powder were purchased from 
Sigma-Aldrich Co. (St. Louis, MO).  Penicillin/Streptomycin antibiotics and Fetal Bovine 
Serum were purchased from Gibco-BRL (Grand Island, NY). Spectrapor dialysis tubing 
(MWCO 15,000) was purchased from Spectrum Laboratories (Rancho Dominguez, CA). 
Sprague-Dawley Male Rats were purchased from Charles-River Laboratories 
(Wilmington, MA). Insulin Radioimmunoassay kits were purchased from MP Biomedical 
(Solon, OH).  
A.3.2. Synthesis of Exendin-4/Polymer Conjugate 
The poly(N-vinyl-2-pyrrolidone-co-acrylic acid) (VA) polymer backbone was the 
same material previously created in our lab [114]. The backbone was activated and 
attached to poly(ethylene glycol) (PEG) using a previously reported method [13]. In 
brief, 1.5g VA was dissolved in 100mL of DMF with the addition of DCC, NHS, and TEA. 
After reacting for 48 hours at room temperature under nitrogen atmosphere, the 
mixture was precipitated twice in anhydrous diethyl ether, dried under vacuum, and 
stored until further use. To link the PEG3400 spacer, 130mg of PEG was dissolved in 10mL 
DMF with 0.1mL TEA for 1 hour and then mixed with activated VA in DMF with TEA. The 
reaction was carried out at room temperature for 48 hours under nitrogen atmosphere. 
The product was dialyzed against distilled water for 5 days (MWCO 15kDa). The dialyzed 
solution was collected and lyophilized and the PEG-VA (VAP) powder was stored until 
further use.  
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The final step was to conjugate Exendin-4 to the PEG-VA construct. Twenty 
milligrams of VAP was dissolved in 10mL dimethyl sulfoxide (DMSO) containing TEA and 
reacted for 24 hours at room temperature under nitrogen atmosphere to activate the 
PEG. Exendin-4 (5mg) was added and the reaction was continued for another 24 hours 
at room temperature under nitrogen atmosphere. The polymer solution was dialyzed 
against distilled water for 5 days using MWCO 15,000 membrane. The final product 
VAPE was obtained following lyophilization and stored at –20°C until further use. 
Chemical conjugation of the peptide was confirmed by HPLC. Exendin-4 content in the 
conjugate was determined by UV spectroscopy, and bioactivity of VAPE was confirmed 
through a glucose-challenge test using rat pancreatic islets.  
A.3.3. Islet Isolation 
Rat islets were freshly isolated from the pancreas of male Sprague-Dawley rats 
using standard collagenase digestion and Ficoll gradient methods [115, 116]. Islets were 
cultured in RPMI 1640 medium supplemented with 10% FBS and 1% Penicillin and 
Streptomycin for 48 hours prior to experimentation.  
A.3.4. Free Islet Glucose Challenge Experiment 
Following culture, 20 islets were plated per well in 24-well tissue culture plates 
and rinsed twice with phosphate-buffered saline to remove any residual medium. Islets 
were glucose-starved by incubation in Kreb’s Ringer HEPES (KRH) buffer containing 
2.8mM glucose (50G) for 30 minutes at 37°C. Incubation medium was collected, and 
islets were placed in 16.8mM (300G) glucose-containing KRH buffer to simulate post-
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prandial conditions. The following stimulants were added to the wells: no stimulant, 
free native Exendin-4, or VAPE in varying concentrations from 1nM to 1µM to mimic 
typical fasting and post-meal circulating GLP-1 levels.  Islets were incubated for 1 hour at 
37°C, medium samples were collected and the islets were rinsed and incubated with 
50G buffer for 10 minutes before the next buffer was added. The same procedure was 
repeated using 11.2mM glucose-KRH buffer (200G) and 5.6mM glucose-KRH buffer 
(100G) and samples were collected after each buffer change.  
A.3.5. Islet Encapsulation 
Islets were isolated in the same manner described above followed by 48 hours 
incubation at 37°C prior to encapsulation. Islets were collected and rinsed with 0.9% 
normal saline solution twice before encapsulation to remove any residual medium. 
Islets were mixed with 4% alginate solution to make a final alginate concentration of 3%. 
For control capsules, islets only were mixed with alginate, for capsules containing VAPE - 
the VAPE was mixed with the islets prior to adding alginate. The islet/alginate mixture 
was loaded into the Nisco Encapsulation Unit type V1 (Zurich, Switzerland) and capsules 
were extruded (flowrate - 5.0mL/hr, 60% agitation, 5.6mV) through a 0.5mm OD needle 
into 50mM CaCl2 solution and stirred for 20 minutes to allow capsule hardening. 
Capsules were collected and rinsed twice with 0.9% normal saline and incubated in 
0.05% Poly-L-Lysine (PLL) solution for 10 minutes. Capsules were rinsed twice with 0.9% 
normal saline and incubated with 0.3% alginate solution for 10 minutes. The capsules 
were coated once more with PLL and then alginate to create the five-layer capsule 
membrane (scheme 1). The final step was to expose the capsules to EGTA for 5 minutes 
182 
 
to liquefy the capsule core. Capsules were collected and placed in RPMI1640 medium 
and stored in the incubator at 37°C for 24 hours before further experimentation.  
A.3.6. Encapsulated Islet Glucose Challenge 
Encapsulated islets were placed in 24-well tissue culture plates for all glucose 
challenge experiments. Each well received 20 encapulated islets and experimental 
conditions were run at least in triplicate. Cell culture well inserts were used to minimize 
capsule loss during experimentation. Glucose challenge experiments were carried out in 
the same manner as described above for free islets. Briefly, capsules were rinsed in 
2.8mM glucose KRH medium (50G) to remove any residual medium, and then incubated 
in fresh 50G medium for 30 minutes to simulate starvation glucose levels. Capsules were 
then cycled through 16.8mM (300G) glucose, 11.2mM (200G) glucose, and 5.6mM 
(100G) glucose containing KRH buffer. Capsules were incubated in 50G buffer for 10 
minutes in between each buffer change to stop any stimulatory effect from the previous 
conditions from carrying over. Buffer samples were collected from the initial 50G 
incubation and after each of the 300G, 200G, and 100G incubations and stored at -20°C 
until analysis using insulin radioimmunoassay kits. All samples collected from the 
glucose challenge experiments were assayed for insulin content using I125 labeled 
insulin antibody radioimmunoassay kits. Samples were read using a Beckman-Coulter 
Gamma Counter.  
The statistical significance of the data was evaluated by conducting unpaired 
Student’s t-test with a confidence level of p<0.05.  
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A.4. Results and Discussion 
A.4.1. Synthesis and Characterization of Exendin-4/polymer Conjugate 
 The previously synthesized poly(N-vinyl-2-pyrrolidone-co-acrylic acid) (VA) polymer 
backbone was activated and conjugated to polyethylene glycol (MW3400) (PEG) through an 
amide linkage to form VA-PEG (VAP). Conjugation of the PEG to the backbone was verified by 
1H-NMR and mass spectrometry. NMR Spectra were taken in d6-DMSO and the formation of VAP 
was confirmed. After determining that the PEG had been attached to the backbone, the 
carboxyl-end of the conjugate was activated and bound to Exendin-4 peptide through a second 
amide linkage to form the Exendin-4/VAP conjugate (VAPE), which was verified by 1H-NMR and 
HPLC. Conjugation of Exendin-4 was confirmed by the NMR spectra taken in d6-DMSO. HPLC 
analysis showed that the VAPE conjugate displayed a peak corresponding to Exendin-4 that was 
absent in samples containing the polymer backbone only (VA) and the backbone conjugated to 
PEG (VAP), indicating the peptide was bound to the backbone. Exendin-4 contains a tryptophan 
residue which displays characteristic absorption at 280nm wavelength after exposure to UV. 
This was useful in determining the amount of Exendin-4 incorporated into the final polymer 
conjugate, which was determined to be 30% by weight using UV spectroscopy.  
 Following the formation of the conjugate, peptide activity of Exendin-4 was 
assessed to determine whether it was still patent or if its bioactivity was lost during 
conjugation. Free pancreatic islets were subjected to a glucose challenge test to 
determine insulin output. Islets received either free Exendin-4 peptide or the VAPE 
conjugate in conjunction with their exposure to buffer containing 16.8mM glucose and 
the buffer sample was assayed for insulin content using radioimmunoassay techniques. 
Insulin release was similar for both the free Exendin-4 and VAPE groups (p=0.92), 
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indicating that the peptide retained its bioactivity following the conjugation reaction 
(figure A-4).  Insulin output did not differ significantly between islets exposed to VAPE 
and control islets following exposure to lower glucose levels (2.8mM and 5.6mM 
glucose), indicating that as expected, VAPE did not stimulate insulin secretion at lower 
levels of glucose. However upon increasing glucose levels to 16.8mM, insulin output 
increased over 300% when islets were exposed to VAPE compared to control islets (p = 
0.0016) indicating that the VAPE was able to stimulate insulin production in the islets in 
response to elevated glucose levels (Figure A-4).  
A.4.2. Characterization of Encapsulated Islets 
 
 Islets were encapsulated in a 5-layer alginate-poly-L-Lysine microcapsule. 
Following encapsulation islets were incubated for 24 hours before being selected for 
further experiments. As shown in Figure A-5, capsules were perfectly spherical with 1-2 
islets encapsulated within the core. Islets were encapsulated either with or without 
VAPE and subjected to glucose challenge experiments to see if encapsulation changed 
the islets’ response to increased glucose levels.  
 Encapsulated islets were also cultured over a few weeks to determine whether 
the system responded to repeated glucose stimulation over time. Encapsulated islets 
were subjected to glucose challenge conditions daily over 14 days and insulin secretion 
was determined by radioimmunoassay. Insulin secretion from the control encapsulated 
islets decreased rapidly over the 14-day period and continued to decrease over the 
entire 8 weeks, while insulin secretion from islets encapsulated with VAPE remained 

















entire 8 weeks, and remained consistently higher than the control (Figure A-6). In 
comparing the insulin secretion levels between control encapsulated islets and islets 
encapsulated with VAPE, the percent of insulin secretion was significantly higher from 
islets encapsulated with VAPE because insulin secretion remained relatively stable while 
insulin secretion from the control islets declined sharply after day 5 (Figure A-6). This 
could be because Exendin-4 had some protective effect on the islet cells and decreased 
the rate at which beta cells succumbed to apoptosis.  
A.5. Conclusions 
An Exendin-4/polymer conjugate was successfully created that was effective in 
significantly increasing the insulin output from pancreatic islets in response to elevated 
glucose levels. In addition, the conjugate did not have any stimulatory effect on the 
islets when glucose levels were low, which would be beneficial in preventing accidental 
hypoglycemic events. Islets encapsulated with VAPE maintained constant insulin 
secretion levels in response to cyclic changes in glucose concentration over two weeks, 
indicating continued functionality and responsiveness over time. This polymer may be a 
good candidate to reduce the number of islets required for a single islet transplantation 
procedure.   
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